Experimental	O
expression	O
in	O
mice	O
and	O
spontaneous	O
expression	O
in	O
human	O
SLE	O
of	O
polyomavirus	B-protein
T-antigen	I-protein
.	O

A	O
molecular	O
basis	O
for	O
induction	O
of	O
antibodies	B-protein
to	O
DNA	O
and	O
eukaryotic	B-protein
transcription	I-protein
factors	I-protein
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
expression	O
of	O
the	O
polyomavirus	B-protein
transcription	I-protein
factor	I-protein
T-antigen	I-protein
has	O
the	O
potential	O
to	O
induce	O
anti-DNA	B-protein
antibodies	I-protein
in	O
mice	O
.	O

Two	O
sets	O
of	O
independent	O
evidences	O
are	O
presented	O
here	O
that	O
demonstrate	O
a	O
biological	O
relevance	O
for	O
this	O
model	O
.	O

First	O
,	O
we	O
describe	O
results	O
demonstrating	O
that	O
mice	O
inoculated	O
with	O
T-antigen-expressing	B-DNA
plasmids	I-DNA
produced	O
antibodies	B-protein
,	O
not	O
only	O
to	O
T-antigen	B-protein
and	O
DNA	O
,	O
but	O
also	O
to	O
the	O
DNA-binding	B-protein
eukaryotic	I-protein
transcription	I-protein
factors	I-protein
TATA-binding	B-protein
protein	I-protein
(	O
TBP	B-protein
)	O
,	O
and	O
to	O
the	O
cAMP-response-element-binding	B-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O

Secondly	O
,	O
we	O
investigated	O
whether	O
polyomavirus	O
reactivation	O
occurs	O
in	O
SLE	O
patients	O
,	O
and	O
whether	O
antibodies	B-protein
to	O
T-antigen	B-protein
,	O
DNA	O
,	O
and	O
to	O
TBP	B-protein
and	O
CREB	B-protein
are	O
linked	O
to	O
such	O
events	O
.	O

Both	O
within	O
and	O
among	O
these	O
SLE	O
patients	O
,	O
frequent	O
polyomavirus	O
reactivations	O
were	O
observed	O
that	O
could	O
not	O
be	O
explained	O
by	O
certain	O
rearrangements	O
of	O
the	O
noncoding	O
control	O
regions	O
,	O
nor	O
by	O
corticosteroid	O
treatment	O
.	O

Linked	O
to	O
these	O
events	O
,	O
antibodies	B-protein
to	O
T-antigen	B-protein
,	O
DNA	O
,	O
TBP	B-protein
,	O
and	O
CREB	B-protein
were	O
detected	O
,	O
identical	O
to	O
what	O
we	O
observed	O
in	O
mice	O
.	O

Antibodies	O
recognizing	O
double-stranded	O
DNA	O
were	O
confined	O
to	O
patients	O
with	O
frequent	O
polyomavirus	O
reactivations	O
.	O

The	O
results	O
described	O
here	O
indicate	O
that	O
cognate	O
interaction	O
of	O
B	O
cells	O
recognizing	O
DNA	O
or	O
DNA-associated	B-protein
proteins	I-protein
and	O
T	B-cell_type
cells	I-cell_type
recognizing	O
T	B-protein
antigen	I-protein
had	O
taken	O
place	O
as	O
a	O
consequence	O
of	O
complex	O
formation	O
between	O
T	B-protein
ag	I-protein
and	O
DNA	O
in	O
vivo	O
in	O
the	O
context	O
of	O
polyomavirus	O
reactivations	O
.	O

Experimental	NULL
Expression	NULL
in	NULL
Mice	NULL
and	NULL
Spontaneous	NULL
Expression	NULL
in	NULL
Human	NULL
SLE	NULL
of	NULL
Polyomavirus	NULL
T-antigen	NULL
A	NULL
Molecular	NULL
Basis	NULL
for	NULL
Induction	NULL
of	NULL
Antibodies	NULL
to	NULL
DNA	NULL
and	NULL
Eukaryotic	NULL
Transcription	NULL
Factors	NULL
Ole	NULL
Petter	NULL
Rekvig	NULL
,	NULL
*	NULL
Ugo	NULL
Moens	NULL
,	NULL
t	NULL
Arnfinn	NULL
Sundsfjord	NULL
,	NULL
$	NULL
Geir	NULL
Bredholt	NULL
,	NULL
*	NULL
Awuku	NULL
Osei	NULL
,	NULL
*	NULL
Hakon	NULL
Haaheim	NULL
,	NULL
$	NULL
Terje	NULL
Traavik	NULL
,	NULL
t	NULL
Egil	NULL
Arnesen	NULL
,	NULL
and	NULL
Hans-Jacob	NULL
Haga**	NULL
*Department	NULL
of	NULL
Immunology	NULL
,	NULL
University	NULL
Hospital	NULL
of	NULL
Tromsg	NULL
,	NULL
N-9038	NULL
Tromsg	NULL
;	NULL
*Department	NULL
of	NULL
Virology	NULL
and	NULL
§Department	NULL
of	NULL
Medical	NULL
Microbiology	NULL
,	NULL
Institute	NULL
of	NULL
Medical	NULL
Biology	NULL
;	NULL
Institute	NULL
of	NULL
Community	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Tromsg	NULL
,	NULL
N-9037	NULL
Tromsg	NULL
;	NULL
**Department	NULL
of	NULL
Rheumatology	NULL
,	NULL
University	NULL
Hospital	NULL
of	NULL
Bergen	NULL
,	NULL
N-5021	NULL
,	NULL
Norway	NULL
Abstract	NULL
We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
experimental	NULL
expression	NULL
of	NULL
the	NULL
polyomavirus	NULL
transcription	NULL
factor	NULL
T-antigen	NULL
has	NULL
the	NULL
potential	NULL
to	NULL
induce	NULL
anti-DNA	NULL
antibodies	NULL
in	NULL
mice	NULL
.	NULL

Two	NULL
sets	NULL
of	NULL
independent	NULL
evidences	NULL
are	NULL
presented	NULL
here	NULL
that	NULL
demonstrate	NULL
a	NULL
biological	NULL
relevance	NULL
for	NULL
this	NULL
model	NULL
.	NULL

First	NULL
,	NULL
we	NULL
describe	NULL
results	NULL
demonstrating	NULL
that	NULL
mice	NULL
inoculated	NULL
with	NULL
T-antigen-expressing	NULL
plasmids	NULL
produced	NULL
antibodies	NULL
,	NULL
not	NULL
only	NULL
to	NULL
T-antigen	NULL
and	NULL
DNA	NULL
,	NULL
but	NULL
also	NULL
to	NULL
the	NULL
DNA-binding	NULL
eukaryotic	NULL
transcription	NULL
factors	NULL
TATA-binding	NULL
protein	NULL
(	NULL
TBP	NULL
)	NULL
,	NULL
and	NULL
to	NULL
the	NULL
cAMP	NULL
-response-element-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
.	NULL

Secondly	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
polyomavirus	NULL
reactivation	NULL
occurs	NULL
in	NULL
SLE	NULL
patients	NULL
,	NULL
and	NULL
whether	NULL
antibodies	NULL
to	NULL
T-antigen	NULL
,	NULL
DNA	NULL
,	NULL
and	NULL
to	NULL
TBP	NULL
and	NULL
CREB	NULL
are	NULL
linked	NULL
to	NULL
such	NULL
events	NULL
.	NULL

Both	NULL
within	NULL
and	NULL
among	NULL
these	NULL
SLE	NULL
patients	NULL
,	NULL
frequent	NULL
polyomavirus	NULL
reactivations	NULL
were	NULL
observed	NULL
that	NULL
could	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
certain	NULL
rearrangements	NULL
of	NULL
the	NULL
noncoding	NULL
control	NULL
regions	NULL
,	NULL
nor	NULL
by	NULL
corticosteroid	NULL
treatment	NULL
.	NULL

Linked	NULL
to	NULL
these	NULL
events	NULL
,	NULL
antibodies	NULL
to	NULL
T-antigen	NULL
,	NULL
DNA	NULL
,	NULL
TBP	NULL
,	NULL
and	NULL
CREB	NULL
were	NULL
detected	NULL
,	NULL
identical	NULL
to	NULL
what	NULL
we	NULL
observed	NULL
in	NULL
mice	NULL
.	NULL

Antibodies	NULL
recognizing	NULL
double-stranded	NULL
DNA	NULL
were	NULL
confined	NULL
to	NULL
patients	NULL
with	NULL
frequent	NULL
polyomavirus	NULL
reactivations	NULL
.	NULL

The	NULL
results	NULL
described	NULL
here	NULL
indicate	NULL
that	NULL
cognate	NULL
interaction	NULL
of	NULL
B	NULL
cells	NULL
recognizing	NULL
DNA	NULL
or	NULL
DNA-associated	NULL
proteins	NULL
and	NULL
T	NULL
cells	NULL
recognizing	NULL
T	NULL
antigen	NULL
had	NULL
taken	NULL
place	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
complex	NULL
formation	NULL
between	NULL
T	NULL
ag	NULL
and	NULL
DNA	NULL
in	NULL
vivo	NULL
in	NULL
the	NULL
context	NULL
of	NULL
polyomavirus	NULL
reactivations	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1997	NULL
.	NULL

99:2045-2054	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
antiDNA	NULL
«	NULL
polyomavirus	NULL
«	NULL
noncoding	NULL
control	NULL
region	NULL
«	NULL
T	NULL
antigen	NULL
«	NULL
SLE	NULL
Introduction	NULL
Antibodies	NULL
against	NULL
mammalian	NULL
native	NULL
B-form	NULL
dsDNA	NULL
serve	NULL
as	NULL
diagnostic	NULL
markers	NULL
for	NULL
SLE	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
,	NULL
and	NULL
subgroups	NULL
within	NULL
this	NULL
antibody	NULL
population	NULL
may	NULL
induce	NULL
kidney	NULL
disease	NULL
typical	NULL
for	NULL
SLE	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Genetic	NULL
studies	NULL
strongly	NULL
indicate	NULL
that	NULL
anti-DNA	NULL
Address	NULL
correspondence	NULL
to	NULL
Ole	NULL
Petter	NULL
Rekvig	NULL
,	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
University	NULL
Hospital	NULL
of	NULL
Tromso	NULL
,	NULL
N-9038	NULL
Tromso	NULL
,	NULL
Norway	NULL
.	NULL

Phone	NULL
:	NULL
+47	NULL
776	NULL
45478	NULL
;	NULL
FAX	NULL
:	NULL
+47	NULL
776	NULL
26304	NULL
;	NULL
E-mail	NULL
:	NULL
olepr	NULL
@	NULL
fagmed.uit.no	NULL
Received	NULL
for	NULL
publication	NULL
16	NULL
September	NULL
1996	NULL
and	NULL
accepted	NULL
in	NULL
revised	NULL
form	NULL
3	NULL
February	NULL
1997	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-9738/97/04/2045/10	NULL
$	NULL
2.00	NULL
Volume	NULL
99	NULL
,	NULL
Number	NULL
8	NULL
,	NULL
April	NULL
1997	NULL
,	NULL
2045-2054	NULL
antibodies	NULL
in	NULL
SLE	NULL
derive	NULL
from	NULL
an	NULL
antigen-selective	NULL
stimulus	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

The	NULL
antibodies	NULL
are	NULL
oligoclonal	NULL
,	NULL
somatically	NULL
mutated	NULL
,	NULL
and	NULL
their	NULL
V	NULL
regions	NULL
contain	NULL
structures	NULL
that	NULL
are	NULL
selected	NULL
by	NULL
,	NULL
and	NULL
favor	NULL
binding	NULL
to	NULL
,	NULL
dsDNA	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Highly	NULL
similar	NULL
SLE-related	NULL
antiDNA	NULL
antibodies	NULL
(	NULL
with	NULL
regard	NULL
to	NULL
specificity	NULL
and	NULL
structure	NULL
of	NULL
their	NULL
V-regions	NULL
)	NULL
can	NULL
be	NULL
experimentally	NULL
induced	NULL
by	NULL
artificial	NULL
DNA-polypeptide	NULL
complexes	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

During	NULL
recent	NULL
years	NULL
,	NULL
we	NULL
developed	NULL
an	NULL
experimental	NULL
model	NULL
that	NULL
allowed	NULL
us	NULL
to	NULL
investigate	NULL
the	NULL
role	NULL
and	NULL
origin	NULL
of	NULL
one	NULL
DNA-binding	NULL
protein	NULL
as	NULL
a	NULL
molecular	NULL
basis	NULL
for	NULL
rendering	NULL
DNA	NULL
immunogenic	NULL
.	NULL

In	NULL
a	NULL
series	NULL
of	NULL
experiments	NULL
using	NULL
intact	NULL
polyomavirus	NULL
particles	NULL
or	NULL
viral	NULL
DNA-protein	NULL
complexes	NULL
as	NULL
immunogens	NULL
,	NULL
all	NULL
animals	NULL
responded	NULL
by	NULL
producing	NULL
anti-DNA	NULL
antibodies	NULL
,	NULL
some	NULL
of	NULL
which	NULL
also	NULL
bound	NULL
to	NULL
the	NULL
supercoiled	NULL
kinetoplast	NULL
DNA	NULL
of	NULL
Crithidia	NULL
luciliae	NULL
(	NULL
12	NULL
)	NULL
,	NULL
demonstrating	NULL
a	NULL
specificity	NULL
for	NULL
dsDNA	NULL
(	NULL
for	NULL
review	NULL
see	NULL
reference	NULL
13	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
presented	NULL
evidence	NULL
that	NULL
a	NULL
linked	NULL
immune	NULL
response	NULL
to	NULL
ssDNA	NULL
,	NULL
dsDNA	NULL
,	NULL
and	NULL
histones	NULL
,	NULL
relied	NULL
on	NULL
the	NULL
DNA-binding	NULL
property	NULL
of	NULL
the	NULL
virus-encoded	NULL
T-antigen	NULL
transcription	NULL
factor	NULL
(	NULL
T-ag	NULL
)	NULL
'	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
experimental	NULL
systems	NULL
described	NULL
so	NULL
far	NULL
have	NULL
,	NULL
therefore	NULL
,	NULL
provided	NULL
insight	NULL
into	NULL
the	NULL
hitherto	NULL
unresolved	NULL
problem	NULL
of	NULL
how	NULL
DNA	NULL
may	NULL
be	NULL
rendered	NULL
immunogenic	NULL
.	NULL

The	NULL
structural	NULL
basis	NULL
for	NULL
the	NULL
development	NULL
of	NULL
such	NULL
antibodies	NULL
in	NULL
vivo	NULL
has	NULL
,	NULL
however	NULL
,	NULL
not	NULL
been	NULL
identified	NULL
.	NULL

The	NULL
experimental	NULL
polyomavirus	NULL
model	NULL
for	NULL
induction	NULL
of	NULL
antibodies	NULL
to	NULL
DNA	NULL
and	NULL
dsDNA	NULL
may	NULL
also	NULL
prove	NULL
useful	NULL
in	NULL
this	NULL
context	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
human	NULL
individuals	NULL
harbor	NULL
silent	NULL
polyomavirus	NULL
infections	NULL
for	NULL
their	NULL
lifetimes	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Normally	NULL
,	NULL
virus	NULL
reactivations	NULL
are	NULL
rare	NULL
.	NULL

Little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
cell	NULL
tropism	NULL
for	NULL
polyomaviruses	NULL
,	NULL
but	NULL
the	NULL
kidneys	NULL
seem	NULL
to	NULL
be	NULL
the	NULL
major	NULL
focus	NULL
,	NULL
both	NULL
for	NULL
primary	NULL
infection	NULL
,	NULL
and	NULL
also	NULL
for	NULL
reactivations	NULL
(	NULL
17	NULL
)	NULL
.	NULL

During	NULL
such	NULL
events	NULL
,	NULL
virus	NULL
particles	NULL
are	NULL
shedded	NULL
in	NULL
the	NULL
urine	NULL
.	NULL

Performing	NULL
PCR	NULL
using	NULL
primers	NULL
for	NULL
viral	NULL
DNA	NULL
has	NULL
therefore	NULL
been	NULL
widely	NULL
used	NULL
for	NULL
detecting	NULL
polyomavirus	NULL
reactivations	NULL
.	NULL

Thus	NULL
,	NULL
consecutive	NULL
urine	NULL
samples	NULL
from	NULL
humans	NULL
may	NULL
be	NULL
assayed	NULL
for	NULL
viral	NULL
DNA	NULL
shedding	NULL
,	NULL
and	NULL
serial	NULL
serum	NULL
samples	NULL
may	NULL
be	NULL
assayed	NULL
for	NULL
development	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
,	NULL
reflecting	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
viral	NULL
transcription	NULL
factor	NULL
T-ag	NULL
.	NULL

The	NULL
simultaneous	NULL
presence	NULL
of	NULL
viral	NULL
DNA	NULL
sequences	NULL
in	NULL
urine	NULL
samples	NULL
and	NULL
anti-T-ag	NULL
antibodies	NULL
in	NULL
serum	NULL
samples	NULL
of	NULL
individual	NULL
patients	NULL
may	NULL
reflect	NULL
virus	NULL
reactivation	NULL
.	NULL

In	NULL
the	NULL
present	NULL
report	NULL
,	NULL
we	NULL
performed	NULL
two	NULL
lines	NULL
of	NULL
experiments	NULL
that	NULL
demonstrate	NULL
a	NULL
central	NULL
role	NULL
for	NULL
polyomavirus	NULL
T-ag	NULL
to	NULL
give	NULL
immunogenic	NULL
potential	NULL
to	NULL
nucleosomal	NULL
antigens	NULL
.	NULL

In	NULL
a	NULL
first	NULL
set	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
inoculated	NULL
Balb/C	NULL
mice	NULL
(	NULL
a	NULL
)	NULL
with	NULL
1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CT	NULL
,	NULL
calf	NULL
thymus	NULL
;	NULL
CREB	NULL
,	NULL
cAMP	NULL
response-element-binding	NULL
protein	NULL
;	NULL
NCCR	NULL
,	NULL
noncoding	NULL
control	NULL
region	NULL
;	NULL
RF	NULL
,	NULL
rheumatoid	NULL
factor	NULL
;	NULL
T-ag	NULL
,	NULL
T-antigen	NULL
;	NULL
TBP	NULL
,	NULL
TATA-binding	NULL
protein	NULL
.	NULL

Polyomaviruses	NULL
and	NULL
Autoimmunity	NULL
to	NULL
DNA	NULL
in	NULL
SLE	NULL
__	NULL
2045	NULL
plasmids	NULL
encoding	NULL
T-ag	NULL
under	NULL
the	NULL
control	NULL
of	NULL
constitutive	NULL
eukaryotic	NULL
promoters	NULL
,	NULL
and	NULL
(	NULL
b	NULL
)	NULL
with	NULL
control	NULL
plasmids	NULL
.	NULL

Previous	NULL
similar	NULL
experiments	NULL
(	NULL
14	NULL
)	NULL
have	NULL
demonstrated	NULL
the	NULL
potential	NULL
for	NULL
T-ag	NULL
to	NULL
initiate	NULL
the	NULL
production	NULL
of	NULL
antibodies	NULL
to	NULL
T-ag	NULL
,	NULL
DNA	NULL
,	NULL
dsDNA	NULL
,	NULL
and	NULL
histone	NULL
antigens	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
confirm	NULL
these	NULL
results	NULL
,	NULL
and	NULL
extend	NULL
the	NULL
observations	NULL
by	NULL
including	NULL
the	NULL
detection	NULL
of	NULL
antibodies	NULL
to	NULL
the	NULL
DNA-binding	NULL
eukaryotic	NULL
transcription	NULL
factors	NULL
TBP	NULL
(	NULL
TATA-binding	NULL
protein	NULL
)	NULL
and	NULL
CREB	NULL
(	NULL
cAMP	NULL
response-element-binding	NULL
protein	NULL
)	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

These	NULL
are	NULL
novel	NULL
,	NULL
not	NULL
previously	NULL
described	NULL
autoantibodies	NULL
.	NULL

In	NULL
a	NULL
second	NULL
set	NULL
of	NULL
observations	NULL
,	NULL
we	NULL
have	NULL
taken	NULL
advantage	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
virtually	NULL
all	NULL
individuals	NULL
are	NULL
latently	NULL
infected	NULL
by	NULL
polyomaviruses	NULL
.	NULL

This	NULL
allows	NULL
us	NULL
to	NULL
investigate	NULL
whether	NULL
polyomavirus	NULL
reactivation	NULL
,	NULL
initiated	NULL
by	NULL
active	NULL
expression	NULL
of	NULL
the	NULL
T-ag	NULL
,	NULL
is	NULL
sufficient	NULL
for	NULL
initiating	NULL
antibody	NULL
production	NULL
against	NULL
the	NULL
same	NULL
set	NULL
of	NULL
autoantibodies	NULL
as	NULL
those	NULL
detected	NULL
in	NULL
mice	NULL
inoculated	NULL
with	NULL
T-ag-expressing	NULL
plasmids	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
observations	NULL
in	NULL
mice	NULL
inoculated	NULL
with	NULL
T-ag-expressing	NULL
plasmids	NULL
,	NULL
antibodies	NULL
to	NULL
ssDNA	NULL
,	NULL
dsDNA	NULL
,	NULL
TBP	NULL
,	NULL
and	NULL
CREB	NULL
were	NULL
,	NULL
with	NULL
one	NULL
exception	NULL
,	NULL
confined	NULL
to	NULL
individuals	NULL
demonstrating	NULL
polyomavirus	NULL
reactivations	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
PCR	NULL
analyses	NULL
of	NULL
serial	NULL
urine	NULL
samples	NULL
,	NULL
and	NULL
,	NULL
linked	NULL
to	NULL
such	NULL
events	NULL
,	NULL
by	NULL
development	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
.	NULL

By	NULL
combining	NULL
these	NULL
independent	NULL
results	NULL
,	NULL
we	NULL
may	NULL
now	NULL
be	NULL
able	NULL
to	NULL
envisage	NULL
the	NULL
following	NULL
model	NULL
representing	NULL
one	NULL
natural	NULL
molecular	NULL
bases	NULL
for	NULL
induction	NULL
of	NULL
SLE-related	NULL
anti-DNA	NULL
antibodies	NULL
.	NULL

Silent	NULL
(	NULL
latent	NULL
)	NULL
polyomavirus	NULL
infection	NULL
may	NULL
be	NULL
terminated	NULL
by	NULL
expression	NULL
of	NULL
T-ag	NULL
.	NULL

This	NULL
termination	NULL
may	NULL
in	NULL
turn	NULL
result	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
complexes	NULL
between	NULL
T-ag	NULL
and	NULL
DNA	NULL
,	NULL
rendering	NULL
DNA	NULL
and	NULL
DNA-associated	NULL
self	NULL
proteins	NULL
like	NULL
TBP	NULL
and	NULL
CREB	NULL
immunogenic	NULL
.	NULL

Methods	NULL
Mice	NULL
.	NULL

2-mo-old	NULL
Balb/C	NULL
mice	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
Charles	NULL
River	NULL
Breeding	NULL
Laboratories	NULL
(	NULL
Sultzfeld	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
and	NULL
were	NULL
housed	NULL
in	NULL
the	NULL
facilities	NULL
of	NULL
the	NULL
Animal	NULL
Research	NULL
Department	NULL
at	NULL
the	NULL
Institute	NULL
of	NULL
Medical	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
Tromsg	NULL
,	NULL
Tromsg	NULL
,	NULL
Norway	NULL
.	NULL

Plasmids	NULL
.	NULL

The	NULL
plasmids	NULL
pReCMV-BLT	NULL
,	NULL
pReCMV-SLT	NULL
,	NULL
pRe-CMV-SLTissrss	NULL
,	NULL
and	NULL
pBS-BLT	NULL
have	NULL
been	NULL
characterized	NULL
in	NULL
detail	NULL
elsewhere	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Inoculation	NULL
of	NULL
plasmids	NULL
.	NULL

Groups	NULL
of	NULL
five	NULL
Balb/C	NULL
mice	NULL
were	NULL
injected	NULL
with	NULL
a	NULL
total	NULL
of	NULL
100	NULL
pg	NULL
of	NULL
the	NULL
individual	NULL
plasmids	NULL
per	NULL
animal	NULL
in	NULL
both	NULL
lumbar	NULL
regions	NULL
.	NULL

Sera	NULL
were	NULL
subsequently	NULL
collected	NULL
every	NULL
second	NULL
week	NULL
over	NULL
an	NULL
8-wk	NULL
observation	NULL
period	NULL
,	NULL
and	NULL
were	NULL
analyzed	NULL
as	NULL
described	NULL
below	NULL
.	NULL

Patients	NULL
.	NULL

10	NULL
normal	NULL
individuals	NULL
and	NULL
6	NULL
RA	NULL
patients	NULL
were	NULL
followed	NULL
over	NULL
3	NULL
mo	NULL
.	NULL

20	NULL
SLE	NULL
patients	NULL
,	NULL
all	NULL
fulfilling	NULL
four	NULL
or	NULL
more	NULL
of	NULL
the	NULL
Ameri-	NULL
can	NULL
Rheumatism	NULL
Association	NULL
(	NULL
ARA	NULL
)	NULL
classification	NULL
criteria	NULL
for	NULL
SLE	NULL
(	NULL
20	NULL
)	NULL
,	NULL
participated	NULL
in	NULL
this	NULL
study	NULL
over	NULL
approximately	NULL
1	NULL
yr	NULL
.	NULL

The	NULL
normal	NULL
individuals	NULL
and	NULL
RA	NULL
patients	NULL
were	NULL
related	NULL
to	NULL
the	NULL
SLE	NULL
patients	NULL
with	NULL
regard	NULL
to	NULL
race	NULL
(	NULL
Caucasians	NULL
)	NULL
,	NULL
sex	NULL
,	NULL
and	NULL
age	NULL
.	NULL

Serum	NULL
and	NULL
urine	NULL
samples	NULL
.	NULL

Serum	NULL
samples	NULL
,	NULL
collected	NULL
at	NULL
the	NULL
begin-ning	NULL
,	NULL
and	NULL
monthly	NULL
thereafter	NULL
from	NULL
each	NULL
normal	NULL
individual	NULL
,	NULL
RA	NULL
,	NULL
or	NULL
SLE	NULL
patient	NULL
throughout	NULL
the	NULL
observation	NULL
period	NULL
,	NULL
were	NULL
stored	NULL
at	NULL
-=70°C	NULL
until	NULL
they	NULL
were	NULL
analyzed	NULL
for	NULL
antibodies	NULL
to	NULL
T-ag	NULL
,	NULL
calf	NULL
thymus	NULL
(	NULL
CT	NULL
)	NULL
ssDNA	NULL
,	NULL
CT	NULL
dsDNA	NULL
,	NULL
TBP	NULL
,	NULL
CREB	NULL
,	NULL
and	NULL
rheumatoid	NULL
factor	NULL
(	NULL
RF	NULL
)	NULL
.	NULL

Urine	NULL
samples	NULL
(	NULL
20	NULL
ml	NULL
)	NULL
(	NULL
approximately	NULL
one	NULL
every	NULL
second	NULL
week	NULL
if	NULL
not	NULL
otherwise	NULL
stated	NULL
in	NULL
Table	NULL
II	NULL
)	NULL
were	NULL
frozen	NULL
by	NULL
the	NULL
patients	NULL
at	NULL
home	NULL
and	NULL
,	NULL
upon	NULL
arrival	NULL
in	NULL
the	NULL
hospital	NULL
,	NULL
were	NULL
stored	NULL
at	NULL
-70°C	NULL
until	NULL
they	NULL
were	NULL
examined	NULL
by	NULL
PCR	NULL
.	NULL

From	NULL
32	NULL
normal	NULL
and	NULL
36	NULL
RA	NULL
patients	NULL
,	NULL
single	NULL
urine	NULL
samples	NULL
were	NULL
also	NULL
collected	NULL
.	NULL

PCR	NULL
amplification	NULL
of	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
in	NULL
urine	NULL
samples	NULL
.	NULL

All	NULL
PCR	NULL
tests	NULL
were	NULL
performed	NULL
following	NULL
the	NULL
guidelines	NULL
cited	NULL
by	NULL
Kwok	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
the	NULL
urine	NULL
samples	NULL
before	NULL
PCR	NULL
analyses	NULL
has	NULL
been	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

For	NULL
the	NULL
detection	NULL
of	NULL
polyomavirus	NULL
early	NULL
gene	NULL
sequences	NULL
,	NULL
the	NULL
PYV	NULL
for	NULL
and	NULL
PYV.rev	NULL
primers	NULL
were	NULL
used	NULL
(	NULL
23	NULL
)	NULL
.	NULL

To	NULL
amplify	NULL
viral	NULL
NCCR	NULL
sequences	NULL
,	NULL
a	NULL
nested	NULL
PCR	NULL
was	NULL
performed	NULL
.	NULL

Initially	NULL
,	NULL
25	NULL
cycles	NULL
were	NULL
run	NULL
with	NULL
the	NULL
primer	NULL
set	NULL
GPPY-1	NULL
and	NULL
GPPY-2	NULL
,	NULL
followed	NULL
by	NULL
30	NULL
cycles	NULL
with	NULL
the	NULL
BKTT-1	NULL
and	NULL
BKTT-10	NULL
primers	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Both	NULL
primer	NULL
sets	NULL
are	NULL
flanking	NULL
the	NULL
viral	NULL
NCCR	NULL
.	NULL

Under	NULL
these	NULL
condi-tions	NULL
,	NULL
0.1	NULL
fg	NULL
of	NULL
polyomavirus	NULL
early	NULL
gene	NULL
sequence	NULL
could	NULL
be	NULL
detected	NULL
(	NULL
17	NULL
genome	NULL
equivalents	NULL
)	NULL
.	NULL

To	NULL
control	NULL
negative	NULL
PCR	NULL
test	NULL
results	NULL
,	NULL
a	NULL
parallel	NULL
sample	NULL
of	NULL
each	NULL
PCR-negative	NULL
urine	NULL
specimen	NULL
was	NULL
amplified	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
1	NULL
fg	NULL
of	NULL
BK	NULL
virus	NULL
DNA	NULL
.	NULL

Amplified	NULL
bands	NULL
of	NULL
expected	NULL
size	NULL
allowed	NULL
the	NULL
conclusion	NULL
that	NULL
PCR-negative	NULL
urine	NULL
samples	NULL
are	NULL
truly	NULL
negative	NULL
.	NULL

To	NULL
distinguish	NULL
between	NULL
polyomavirus	NULL
BK	NULL
or	NULL
JC	NULL
NCCR	NULL
,	NULL
PCR	NULL
products	NULL
were	NULL
digested	NULL
with	NULL
PfimI	NULL
,	NULL
Bsu36I	NULL
and	NULL
SacI	NULL
(	NULL
24-26	NULL
)	NULL
.	NULL

Sequencing	NULL
the	NULL
NCCR	NULL
.	NULL

Amplified	NULL
NCCRs	NULL
were	NULL
sequenced	NULL
twice	NULL
by	NULL
the	NULL
dideoxy	NULL
method	NULL
(	NULL
27	NULL
)	NULL
as	NULL
described	NULL
in	NULL
detail	NULL
elsewhere	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Antigens	NULL
.	NULL

The	NULL
source	NULL
and	NULL
preparation	NULL
of	NULL
T-ag	NULL
,	NULL
CT	NULL
ssDNA	NULL
,	NULL
and	NULL
CT	NULL
dsDNA	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
,	NULL
28	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
factors	NULL
TBP	NULL
and	NULL
CREB	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnol-ogy	NULL
,	NULL
Inc.	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

TBP	NULL
is	NULL
a	NULL
full-length	NULL
human	NULL
protein	NULL
prepared	NULL
as	NULL
a	NULL
glutathione-S-transferase	NULL
(	NULL
GST	NULL
)	NULL
fusion	NULL
protein	NULL
in	NULL
Escherichia	NULL
coli	NULL
,	NULL
while	NULL
CREB	NULL
is	NULL
a	NULL
10-14-kD	NULL
DNA-binding	NULL
domain	NULL
(	NULL
CREB-1	NULL
)	NULL
of	NULL
the	NULL
43-kD	NULL
full-length	NULL
human	NULL
protein	NULL
.	NULL

TBP	NULL
and	NULL
CREB	NULL
were	NULL
>	NULL
98	NULL
%	NULL
pure	NULL
according	NULL
to	NULL
the	NULL
manufacturers	NULL
,	NULL
and	NULL
were	NULL
virtually	NULL
free	NULL
from	NULL
contaminating	NULL
proteins	NULL
according	NULL
to	NULL
SDS-PAGE	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Indirect	NULL
solid	NULL
phase	NULL
ELISA	NULL
.	NULL

For	NULL
detection	NULL
of	NULL
antibodies	NULL
to	NULL
CT	NULL
ssDNA	NULL
,	NULL
CT	NULL
dsDNA	NULL
,	NULL
and	NULL
T-ag	NULL
,	NULL
the	NULL
ELISA	NULL
tests	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
,	NULL
28	NULL
)	NULL
.	NULL

The	NULL
CT	NULL
ssDNA	NULL
used	NULL
as	NULL
ELISA	NULL
antigen	NULL
binds	NULL
both	NULL
anti-ssDNA	NULL
and	NULL
anti-dsDNA	NULL
antibodies	NULL
.	NULL

In	NULL
the	NULL
CT	NULL
dsDNA	NULL
ELISA	NULL
,	NULL
specificity	NULL
for	NULL
dsDNA	NULL
was	NULL
ascertained	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
binding	NULL
of	NULL
the	NULL
monoclonal	NULL
anti-ssDNA	NULL
antibody	NULL
111-185	NULL
(	NULL
29	NULL
)	NULL
,	NULL
while	NULL
the	NULL
monoclonal	NULL
anti-dsDNA	NULL
antibody	NULL
DNAG6	NULL
(	NULL
8	NULL
)	NULL
bound	NULL
to	NULL
this	NULL
antigen	NULL
.	NULL

For	NULL
detection	NULL
of	NULL
antibodies	NULL
to	NULL
TBP	NULL
and	NULL
CREB	NULL
,	NULL
microtiter	NULL
plates	NULL
(	NULL
Nunc	NULL
Maxisorp	NULL
;	NULL
Intermed	NULL
Nunc	NULL
,	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
were	NULL
coated	NULL
with	NULL
TBP	NULL
or	NULL
CREB	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
pg/ml	NULL
in	NULL
PBS	NULL
.	NULL

For	NULL
these	NULL
tests	NULL
,	NULL
serum	NULL
samples	NULL
were	NULL
diluted	NULL
twofold	NULL
from	NULL
1/100	NULL
to	NULL
1/	NULL
Table	NULL
I	NULL
.	NULL

Demonstration	NULL
of	NULL
Antigen-Selective	NULL
Immune	NULL
Responses	NULL
to	NULL
T-ag	NULL
and	NULL
to	NULL
Various	NULL
Nucleosome-associated	NULL
Autoantigens	NULL
in	NULL
BALB/c	NULL
Mice	NULL
Inoculated	NULL
with	NULL
T-ag-expressing	NULL
and	NULL
Control	NULL
Plasmids	NULL
Balb/C	NULL
Mean	NULL
titer	NULL
of	NULL
antibodies	NULL
to	NULL
Plasmid	NULL
Protein	NULL
expressed	NULL
n	NULL
T-antigen	NULL
ssDNA	NULL
TBP	NULL
CREB	NULL
RF	NULL
pReCMV-BLT	NULL
BK	NULL
virus	NULL
T-ag	NULL
5	NULL
248+48	NULL
352+97	NULL
468+254	NULL
552+186	NULL
0	NULL
pReCMV-SLT	NULL
SV40-T-agissr	NULL
5	NULL
314+118	NULL
350+138	NULL
318499	NULL
402+91	NULL
0	NULL
SV40-T-Agi3ss	NULL
5	NULL
282+28	NULL
<	NULL
100*	NULL
346+115	NULL
74+68	NULL
0	NULL
pBS-BLT	NULL
None	NULL
5	NULL
0	NULL
-	NULL
0	NULL
-	NULL
0	NULL
-	NULL
0	NULL
-	NULL
0	NULL
*In	NULL
sera	NULL
from	NULL
these	NULL
mice	NULL
,	NULL
traces	NULL
of	NULL
anti-DNA	NULL
antibodies	NULL
could	NULL
be	NULL
detected	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
,	NULL
but	NULL
the	NULL
OD	NULL
(	NULL
492	NULL
)	NULL
values	NULL
were	NULL
below	NULL
the	NULL
binding	NULL
value	NULL
at	NULL
1/100	NULL
dilution	NULL
necessary	NULL
to	NULL
reach	NULL
a	NULL
titer	NULL
.	NULL

2046	NULL
_	NULL
Rekvig	NULL
et	NULL
al	NULL
.	NULL

3200	NULL
in	NULL
PBS	NULL
(	NULL
0.05	NULL
%	NULL
Tween-20	NULL
)	NULL
.	NULL

To	NULL
ascertain	NULL
that	NULL
serum	NULL
antibodies	NULL
actually	NULL
bound	NULL
to	NULL
TBP	NULL
,	NULL
and	NULL
not	NULL
to	NULL
its	NULL
fusion	NULL
partner	NULL
GST	NULL
,	NULL
the	NULL
sera	NULL
were	NULL
tested	NULL
in	NULL
control	NULL
wells	NULL
coated	NULL
with	NULL
GST	NULL
in	NULL
PBS	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
pg/ml	NULL
.	NULL

These	NULL
ELISAs	NULL
were	NULL
processed	NULL
exactly	NULL
as	NULL
described	NULL
for	NULL
the	NULL
other	NULL
tests	NULL
.	NULL

For	NULL
all	NULL
ELISA	NULL
tests	NULL
,	NULL
only	NULL
Ig	NULL
antibodies	NULL
were	NULL
ana-lyzed	NULL
,	NULL
using	NULL
a	NULL
horseradish	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-human	NULL
Ig	NULL
.	NULL

Titers	NULL
of	NULL
the	NULL
antibodies	NULL
were	NULL
determined	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
ELISA	NULL
tests	NULL
were	NULL
processed	NULL
using	NULL
the	NULL
fully	NULL
automated	NULL
Behring	NULL
ELISA	NULL
processor	NULL
III	NULL
(	NULL
Behringwerke	NULL
AG	NULL
,	NULL
Frankfurt	NULL
a	NULL
.	NULL

Main	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Crithidia	NULL
luciliae	NULL
.	NULL

The	NULL
test	NULL
for	NULL
detection	NULL
of	NULL
antibodies	NULL
to	NULL
dsDNA	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Detection	NULL
of	NULL
RF	NULL
.	NULL

This	NULL
was	NULL
done	NULL
by	NULL
a	NULL
nephelometric	NULL
method	NULL
using	NULL
a	NULL
Nephelometer-Analyzer	NULL
(	NULL
Behring	NULL
,	NULL
Marburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
given	NULL
as	NULL
IU/ml	NULL
,	NULL
using	NULL
the	NULL
reference	NULL
standards	NULL
supplied	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Values	NULL
=	NULL
11	NULL
IU/ml	NULL
are	NULL
regarded	NULL
as	NULL
negative	NULL
.	NULL

Statistics	NULL
.	NULL

Statistical	NULL
testing	NULL
was	NULL
done	NULL
using	NULL
the	NULL
two-way	NULL
analysis	NULL
of	NULL
variance	NULL
with	NULL
patients	NULL
'	NULL
number	NULL
,	NULL
group	NULL
(	NULL
I-IV	NULL
)	NULL
,	NULL
and	NULL
multiple	NULL
regression	NULL
analyses	NULL
as	NULL
factors	NULL
.	NULL

SAS	NULL
software	NULL
was	NULL
used	NULL
(	NULL
SAS	NULL
Institute	NULL
,	NULL
Inc.	NULL
,	NULL
Cary	NULL
,	NULL
NC	NULL
)	NULL
.	NULL

Results	NULL
T-ag	NULL
expression	NULL
in	NULL
plasmid-inoculated	NULL
mice	NULL
.	NULL

Groups	NULL
of	NULL
five	NULL
mice	NULL
were	NULL
given	NULL
a	NULL
single	NULL
injection	NULL
of	NULL
plasmids	NULL
encoding	NULL
wild-type	NULL
T-ag	NULL
from	NULL
polyomavirus	NULL
BK	NULL
(	NULL
pReCMV-BLT	NULL
)	NULL
,	NULL
SV40	NULL
virus	NULL
(	NULL
pReCMV-SLT	NULL
)	NULL
,	NULL
or	NULL
the	NULL
mutant	NULL
SV40	NULL
T-ag	NULL
(	NULL
pReCMV-SLT	NULL
This	NULL
latter	NULL
mutant	NULL
T-ag	NULL
,	NULL
due	NULL
to	NULL
replacement	NULL
of	NULL
one	NULL
amino	NULL
acid	NULL
at	NULL
position	NULL
155	NULL
,	NULL
has	NULL
lost	NULL
its	NULL
ability	NULL
to	NULL
bind	NULL
DNA	NULL
se-quence-specifically	NULL
,	NULL
but	NULL
has	NULL
retained	NULL
a	NULL
weak	NULL
,	NULL
sequence	NULL
nonspe-cific	NULL
affinity	NULL
for	NULL
DNA	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Sera	NULL
collected	NULL
every	NULL
second	NULL
week	NULL
over	NULL
an	NULL
8-wk	NULL
period	NULL
,	NULL
were	NULL
assayed	NULL
for	NULL
Ig	NULL
antibodies	NULL
to	NULL
T-ag	NULL
.	NULL

While	NULL
all	NULL
preimmune	NULL
sera	NULL
from	NULL
these	NULL
mice	NULL
were	NULL
negative	NULL
for	NULL
anti-T-ag	NULL
antibodies	NULL
,	NULL
this	NULL
antibody	NULL
increased	NULL
over	NULL
the	NULL
observation	NULL
time	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A-C	NULL
)	NULL
,	NULL
and	NULL
sera	NULL
drawn	NULL
after	NULL
8	NULL
wk	NULL
contained	NULL
high	NULL
titers	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
,	NULL
indicating	NULL
that	NULL
T-ag	NULL
was	NULL
expressed	NULL
in	NULL
vivo	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Sera	NULL
from	NULL
mice	NULL
inoculated	NULL
with	NULL
the	NULL
plasmid	NULL
containing	NULL
the	NULL
gene	NULL
encoding	NULL
BK	NULL
virus	NULL
T-ag	NULL
,	NULL
but	NULL
lacking	NULL
an	NULL
eukaryotic	NULL
promoter	NULL
(	NULL
pBS-BLT	NULL
)	NULL
,	NULL
were	NULL
negative	NULL
for	NULL
anti-T-ag	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

T-ag	NULL
expression	NULL
and	NULL
initiation	NULL
of	NULL
antibodies	NULL
to	NULL
DNA	NULL
and	NULL
the	NULL
transcription	NULL
factors	NULL
TBP	NULL
and	NULL
CREB	NULL
.	NULL

The	NULL
mice	NULL
that	NULL
received	NULL
the	NULL
plasmids	NULL
expressing	NULL
wild-type	NULL
T-ag	NULL
from	NULL
BK	NULL
or	NULL
SV40	NULL
virus	NULL
,	NULL
but	NULL
not	NULL
those	NULL
inoculated	NULL
with	NULL
the	NULL
pBS-BLT	NULL
plasmid	NULL
,	NULL
developed	NULL
Ig	NULL
antibodies	NULL
to	NULL
ssDNA	NULL
,	NULL
TBP	NULL
,	NULL
and	NULL
CREB	NULL
simultaneously	NULL
with	NULL
the	NULL
initiation	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
(	NULL
Table	NULL
I	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A-B	NULL
)	NULL
.	NULL

In	NULL
mice	NULL
injected	NULL
with	NULL
the	NULL
plasmid	NULL
encoding	NULL
the	NULL
mutant	NULL
T-ag	NULL
,	NULL
antibodies	NULL
to	NULL
T-ag	NULL
and	NULL
to	NULL
TBP	NULL
developed	NULL
in	NULL
a	NULL
similar	NULL
way	NULL
(	NULL
Table	NULL
I	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
only	NULL
three	NULL
out	NULL
of	NULL
the	NULL
five	NULL
mice	NULL
,	NULL
anti-CREB	NULL
antibodies	NULL
were	NULL
detected	NULL
at	NULL
titers	NULL
>	NULL
100	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

In	NULL
the	NULL
two	NULL
other	NULL
mice	NULL
,	NULL
weak	NULL
reactivity	NULL
to	NULL
CREB	NULL
was	NULL
also	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
,	NULL
but	NULL
the	NULL
strength	NULL
was	NULL
below	NULL
the	NULL
level	NULL
necessary	NULL
to	NULL
reach	NULL
a	NULL
titer	NULL
at	NULL
a	NULL
1/100	NULL
serum	NULL
dilution	NULL
.	NULL

None	NULL
of	NULL
these	NULL
mice	NULL
produced	NULL
anti-DNA	NULL
antibodies	NULL
above	NULL
this	NULL
thresh-old	NULL
,	NULL
although	NULL
weak	NULL
reactivities	NULL
could	NULL
also	NULL
be	NULL
detected	NULL
for	NULL
this	NULL
specificity	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
results	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
IgG	NULL
(	NULL
RF	NULL
)	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
any	NULL
of	NULL
these	NULL
sera	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
responses	NULL
to	NULL
the	NULL
other	NULL
antigens	NULL
are	NULL
the	NULL
result	NULL
of	NULL
antigen-selective	NULL
B	NULL
cell	NULL
stimulation	NULL
.	NULL

Correlation	NULL
between	NULL
T-ag	NULL
expression	NULL
in	NULL
vivo	NULL
and	NULL
immune	NULL
responses	NULL
to	NULL
DNA	NULL
,	NULL
dsDNA	NULL
,	NULL
TBP	NULL
,	NULL
and	NULL
CREB	NULL
in	NULL
humans	NULL
.	NULL

As	NULL
indicated	NULL
above	NULL
,	NULL
PCR-based	NULL
detection	NULL
of	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
in	NULL
urine	NULL
samples	NULL
,	NULL
combined	NULL
with	NULL
development	NULL
of	NULL
Figure	NULL
1	NULL
.	NULL

Immune	NULL
responses	NULL
to	NULL
T-ag	NULL
(	NULL
K	NULL
)	NULL
,	NULL
DNA	NULL
(	NULL
¥	NULL
)	NULL
,	NULL
TBP	NULL
(	NULL
@	NULL
)	NULL
and	NULL
CREB	NULL
(	NULL
0	NULL
)	NULL
in	NULL
groups	NULL
of	NULL
mice	NULL
given	NULL
a	NULL
single	NULL
injection	NULL
of	NULL
the	NULL
T-ag-encoding	NULL
plasmids	NULL
pReCMV-BLT	NULL
(	NULL
A4	NULL
,	NULL
solid	NULL
lines	NULL
)	NULL
,	NULL
pBS-BLT	NULL
(	NULL
A	NULL
,	NULL
broken	NULL
lines	NULL
)	NULL
,	NULL
pReCMV-SLT	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
pReCMV-SLT	NULL
{	NULL
s37-ss	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
given	NULL
as	NULL
mean	NULL
+SD	NULL
of	NULL
the	NULL
absorbance	NULL
at	NULL
492	NULL
nm	NULL
,	NULL
representing	NULL
antibody	NULL
binding	NULL
at	NULL
serum	NULL
dilution	NULL
1/100	NULL
for	NULL
all	NULL
tests	NULL
.	NULL

anti-T-ag	NULL
antibodies	NULL
,	NULL
are	NULL
regarded	NULL
as	NULL
evidence	NULL
for	NULL
polyomavirus	NULL
reactivation	NULL
.	NULL

These	NULL
parameters	NULL
were	NULL
therefore	NULL
selected	NULL
to	NULL
investigate	NULL
whether	NULL
the	NULL
processes	NULL
resulting	NULL
in	NULL
antibodies	NULL
to	NULL
T-ag	NULL
,	NULL
DNA	NULL
,	NULL
TBP	NULL
,	NULL
and	NULL
CREB	NULL
after	NULL
experimental	NULL
T-ag	NULL
expression	NULL
in	NULL
mice	NULL
reflect	NULL
similar	NULL
processes	NULL
in	NULL
humans	NULL
,	NULL
particularly	NULL
in	NULL
those	NULL
with	NULL
SLE	NULL
.	NULL

Prevalence	NULL
and	NULL
frequency	NULL
of	NULL
human	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
in	NULL
urine	NULL
samples	NULL
from	NULL
healthy	NULL
individuals	NULL
and	NULL
RA	NULL
patients	NULL
.	NULL

Single	NULL
urine	NULL
samples	NULL
from	NULL
32	NULL
healthy	NULL
and	NULL
36	NULL
RA	NULL
individuals	NULL
were	NULL
analyzed	NULL
.	NULL

Except	NULL
for	NULL
one	NULL
urine	NULL
sample	NULL
taken	NULL
from	NULL
an	NULL
RA	NULL
patient	NULL
,	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
were	NULL
not	NULL
Polyomaviruses	NULL
and	NULL
Autoimmunity	NULL
to	NULL
DNA	NULL
in	NULL
SLE	NULL
__	NULL
2047	NULL
Table	NULL
II	NULL
.	NULL

PCR-amplified	NULL
Polyomavirus	NULL
DNA	NULL
Sequences	NULL
in	NULL
Urine	NULL
Samples	NULL
,	NULL
and	NULL
Mean	NULL
Anti-T-ag	NULL
and	NULL
Anti-ssDNA	NULL
Antibody	NULL
Titers	NULL
,	NULL
as	NULL
Determined	NULL
in	NULL
20	NULL
SLE	NULL
Patients	NULL
Analyzed	NULL
Over	NULL
1	NULL
yr	NULL
PCR	NULL
positive	NULL
Anti-T-ag	NULL
titer*	NULL
Anti-DNA	NULL
titer*	NULL
Group	NULL
Patient	NULL
n	NULL
_	NULL
n	NULL
_	NULL
%	NULL
-	NULL
Mean	NULL
SD	NULL
CV	NULL
Mean	NULL
SD	NULL
CV	NULL
I	NULL
7	NULL
16	NULL
0	NULL
0	NULL
0.0	NULL
-	NULL
-	NULL
0.0	NULL
_	NULL
-	NULL
11	NULL
18	NULL
0	NULL
0	NULL
0.0	NULL
-	NULL
-	NULL
0.0	NULL
_	NULL
-	NULL
19	NULL
20	NULL
0	NULL
0	NULL
0.0	NULL
-	NULL
-	NULL
-	NULL
758.0	NULL
101.41	NULL
13.38	NULL
21	NULL
19	NULL
0	NULL
0	NULL
0.0	NULL
_-	NULL
-	NULL
0.0	NULL
_	NULL
-	NULL
II	NULL
9	NULL
18	NULL
1	NULL
6	NULL
41.0	NULL
86.47	NULL
210.90	NULL
21.0	NULL
44.33	NULL
211.12	NULL
13	NULL
27	NULL
1	NULL
4	NULL
31.8	NULL
54.74	NULL
172.04	NULL
21.8	NULL
48.54	NULL
222.49	NULL
III	NULL
2	NULL
22	NULL
20	NULL
9	NULL
26.7	NULL
53.15	NULL
199.32	NULL
11.1	NULL
33.33	NULL
300.00	NULL
4	NULL
33	NULL
7	NULL
21	NULL
217.5	NULL
44.75	NULL
20.57	NULL
146.2	NULL
35.36	NULL
24.18	NULL
IV	NULL
5	NULL
28	NULL
24	NULL
86	NULL
854.6	NULL
109.12	NULL
12.77	NULL
956.4	NULL
277.25	NULL
28.99	NULL
8	NULL
21	NULL
12	NULL
63	NULL
458.0	NULL
24.86	NULL
5.43	NULL
341.0	NULL
121.33	NULL
35.58	NULL
10	NULL
32	NULL
16	NULL
50	NULL
315.5	NULL
105.20	NULL
33.35	NULL
301.8	NULL
113.91	NULL
37.74	NULL
12	NULL
23	NULL
23	NULL
100	NULL
475.0	NULL
39.23	NULL
8.26	NULL
801.0	NULL
126.35	NULL
15.77	NULL
14	NULL
6	NULL
6	NULL
100	NULL
556.6	NULL
76.33	NULL
13.71	NULL
725.0	NULL
66.26	NULL
9.14	NULL
16	NULL
28	NULL
25	NULL
89	NULL
484.5	NULL
67.29	NULL
13.89	NULL
496.8	NULL
77.27	NULL
15.55	NULL
17	NULL
27	NULL
21	NULL
78	NULL
454.5	NULL
42.75	NULL
9.49	NULL
466.4	NULL
158.76	NULL
34.04	NULL
18	NULL
23	NULL
11	NULL
48	NULL
467.8	NULL
96.92	NULL
20.72	NULL
206.7	NULL
76.16	NULL
36.85	NULL
20	NULL
20	NULL
14	NULL
70	NULL
777.0	NULL
164.99	NULL
21.43	NULL
788.0	NULL
256.51	NULL
32.55	NULL
23	NULL
6	NULL
6	NULL
100	NULL
471.3	NULL
25.32	NULL
5.37	NULL
567.5	NULL
90.36	NULL
15.92	NULL
24	NULL
19	NULL
15	NULL
79	NULL
686.7	NULL
77.46	NULL
11.28	NULL
631.1	NULL
155.28	NULL
24.60	NULL
25	NULL
23	NULL
7	NULL
30	NULL
4322	NULL
64.76	NULL
14.98	NULL
532.2	NULL
83.48	NULL
15.69	NULL
*The	NULL
titers	NULL
of	NULL
antibodies	NULL
to	NULL
T-ag	NULL
and	NULL
to	NULL
ssDNA	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
of	NULL
all	NULL
titers	NULL
measured	NULL
over	NULL
the	NULL
observation	NULL
time	NULL
for	NULL
each	NULL
patient	NULL
.	NULL

detected	NULL
in	NULL
any	NULL
of	NULL
these	NULL
samples	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
while	NULL
43	NULL
%	NULL
of	NULL
urine	NULL
samples	NULL
from	NULL
SLE	NULL
patients	NULL
were	NULL
PCR-positive	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

For	NULL
the	NULL
10	NULL
normal	NULL
individuals	NULL
followed	NULL
over	NULL
3	NULL
mo	NULL
,	NULL
none	NULL
of	NULL
the	NULL
urine	NULL
samples	NULL
(	NULL
six	NULL
from	NULL
each	NULL
patient	NULL
)	NULL
contained	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
.	NULL

None	NULL
of	NULL
the	NULL
four	NULL
serum	NULL
samples	NULL
from	NULL
each	NULL
of	NULL
these	NULL
individuals	NULL
contained	NULL
antibodies	NULL
to	NULL
T-ag	NULL
,	NULL
DNA	NULL
,	NULL
TBP	NULL
,	NULL
or	NULL
CREB	NULL
.	NULL

For	NULL
the	NULL
six	NULL
RA	NULL
patients	NULL
followed	NULL
over	NULL
3	NULL
mo	NULL
,	NULL
five	NULL
were	NULL
PCR-	NULL
(	NULL
as	NULL
well	NULL
as	NULL
serum	NULL
antibody	NULL
)	NULL
negative	NULL
.	NULL

For	NULL
one	NULL
,	NULL
however	NULL
,	NULL
four	NULL
out	NULL
of	NULL
six	NULL
urine	NULL
samples	NULL
were	NULL
PCR-positive	NULL
,	NULL
and	NULL
all	NULL
serum	NULL
samples	NULL
from	NULL
this	NULL
patient	NULL
contained	NULL
anti	NULL
bodies	NULL
to	NULL
T-ag	NULL
,	NULL
ssDNA	NULL
,	NULL
TBP	NULL
,	NULL
and	NULL
CREB	NULL
,	NULL
with	NULL
mean	NULL
titers	NULL
of	NULL
219	NULL
,	NULL
147	NULL
,	NULL
312	NULL
,	NULL
and	NULL
289	NULL
,	NULL
respectively	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Frequency	NULL
and	NULL
NCCR	NULL
structure	NULL
of	NULL
polyomavirus	NULL
DNA	NULL
in	NULL
serial	NULL
urine	NULL
samples	NULL
from	NULL
SLE	NULL
patients	NULL
.	NULL

For	NULL
all	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
,	NULL
amplicons	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
primer	NULL
set	NULL
complementary	NULL
to	NULL
T-ag-encoding	NULL
DNA	NULL
sequences	NULL
and	NULL
to	NULL
sequences	NULL
flanking	NULL
NCCR	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
frequency	NULL
of	NULL
urine	NULL
samples	NULL
containing	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
,	NULL
the	NULL
patients	NULL
were	NULL
divided	NULL
into	NULL
four	NULL
groups	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Group	NULL
I	NULL
encompassed	NULL
patients	NULL
7	NULL
,	NULL
11	NULL
,	NULL
19	NULL
,	NULL
and	NULL
21	NULL
,	NULL
whose	NULL
urine	NULL
samples	NULL
were	NULL
negative	NULL
for	NULL
polyomavirus	NULL
DNA	NULL
throughout	NULL
the	NULL
observation	NULL
period	NULL
.	NULL

In	NULL
group	NULL
II	NULL
(	NULL
patients	NULL
9	NULL
and	NULL
13	NULL
)	NULL
,	NULL
one	NULL
single	NULL
PCR-positive	NULL
urine	NULL
sample	NULL
was	NULL
identified	NULL
for	NULL
each	NULL
of	NULL
the	NULL
patients	NULL
.	NULL

Patients	NULL
demonstrating	NULL
few	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
were	NULL
clustered	NULL
in	NULL
group	NULL
III	NULL
,	NULL
with	NULL
patient	NULL
2	NULL
having	NULL
two	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
out	NULL
of	NULL
22	NULL
(	NULL
9	NULL
%	NULL
)	NULL
,	NULL
and	NULL
patient	NULL
4	NULL
having	NULL
seven	NULL
out	NULL
of	NULL
33	NULL
(	NULL
21	NULL
%	NULL
)	NULL
.	NULL

About	NULL
30-100	NULL
%	NULL
of	NULL
the	NULL
urine	NULL
samples	NULL
of	NULL
the	NULL
remaining	NULL
12	NULL
patients	NULL
(	NULL
group	NULL
IV	NULL
)	NULL
were	NULL
PCR-positive	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
total	NULL
number	NULL
of	NULL
urine	NULL
samples	NULL
in	NULL
this	NULL
group	NULL
,	NULL
74	NULL
%	NULL
were	NULL
PCR-positive	NULL
,	NULL
compared	NULL
to	NULL
43	NULL
%	NULL
for	NULL
all	NULL
SLE	NULL
patients	NULL
.	NULL

The	NULL
frequency	NULL
and	NULL
distribution	NULL
of	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
of	NULL
patients	NULL
representative	NULL
for	NULL
groups	NULL
I-IV	NULL
are	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

The	NULL
high	NULL
prevalence	NULL
of	NULL
polyomavirus	NULL
DNA	NULL
in	NULL
the	NULL
urine	NULL
of	NULL
SLE	NULL
patients	NULL
could	NULL
theoretically	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
selection	NULL
of	NULL
virus	NULL
strains	NULL
with	NULL
certain	NULL
NCCRs	NULL
known	NULL
to	NULL
dispose	NULL
for	NULL
reactivation	NULL
(	NULL
15	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Duplication	NULL
of	NULL
P-blocks	NULL
(	NULL
31	NULL
)	NULL
of	NULL
BK	NULL
virus	NULL
NCCR	NULL
have	NULL
been	NULL
particularly	NULL
ascribed	NULL
this	NULL
effect	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
these	NULL
NCCRs	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
,	NULL
however	NULL
,	NULL
were	NULL
almost	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
the	NULL
archetypal	NULL
polyomavirus	NULL
BK	NULL
(	NULL
31	NULL
)	NULL
or	NULL
JC	NULL
(	NULL
24	NULL
)	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
restriction	NULL
enzyme	NULL
patterns	NULL
of	NULL
the	NULL
amplified	NULL
NCCR	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
sequences	NULL
except	NULL
the	NULL
one	NULL
in	NULL
patient	NULL
2	NULL
,	NULL
that	NULL
contained	NULL
an	NULL
unreported	NULL
BK	NULL
virus	NULL
NCCR	NULL
(	NULL
denoted	NULL
AO	NULL
)	NULL
,	NULL
are	NULL
all	NULL
found	NULL
among	NULL
normal	NULL
individuals	NULL
.	NULL

Corticosteroid	NULL
treatment	NULL
and	NULL
polyomavirus	NULL
reactivations	NULL
.	NULL

As	NULL
the	NULL
strong	NULL
tendency	NULL
for	NULL
virus	NULL
reactivation	NULL
could	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
selection	NULL
of	NULL
certain	NULL
transcriptional	NULL
active	NULL
NCCRs	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
patients	NULL
with	NULL
steroid	NULL
hormones	NULL
,	NULL
which	NULL
have	NULL
been	NULL
shown	NULL
in	NULL
vitro	NULL
to	NULL
increase	NULL
the	NULL
permissivity	NULL
of	NULL
cells	NULL
for	NULL
BK	NULL
virus	NULL
(	NULL
32	NULL
)	NULL
,	NULL
could	NULL
alternatively	NULL
account	NULL
for	NULL
the	NULL
enhanced	NULL
productive	NULL
polyomavirus	NULL
infection	NULL
among	NULL
these	NULL
patients	NULL
.	NULL

This	NULL
can	NULL
not	NULL
,	NULL
however	NULL
,	NULL
be	NULL
the	NULL
explanation	NULL
for	NULL
the	NULL
strong	NULL
tendency	NULL
for	NULL
polyomavirus	NULL
reactivations	NULL
,	NULL
as	NULL
SLE	NULL
patients	NULL
8	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
23	NULL
,	NULL
and	NULL
24	NULL
,	NULL
all	NULL
with	NULL
frequent	NULL
reactivations	NULL
,	NULL
did	NULL
not	NULL
receive	NULL
corticoste-roids	NULL
during	NULL
the	NULL
observation	NULL
period	NULL
.	NULL

Table	NULL
III	NULL
.	NULL

Anatomy	NULL
of	NULL
the	NULL
Noncoding	NULL
Control	NULL
Region	NULL
(	NULL
NCCR	NULL
)	NULL
of	NULL
the	NULL
Polyomaviruses	NULL
BK	NULL
or	NULL
JC	NULL
Detected	NULL
in	NULL
the	NULL
Urine	NULL
Samples	NULL
of	NULL
SLE	NULL
patients	NULL
.	NULL

The	NULL
NCCRs	NULL
Were	NULL
Compared	NULL
to	NULL
the	NULL
Consensus	NULL
Sequence	NULL
of	NULL
the	NULL
Archetypal	NULL
BK	NULL
Virus	NULL
WW	NULL
or	NULL
the	NULL
JC	NULL
Virus	NULL
CY	NULL
Strains	NULL
(	NULL
24	NULL
,	NULL
31	NULL
)	NULL
Virus	NULL
Patients*	NULL
Strain	NULL
NCCR	NULL
anatomy	NULL
BK	NULL
4,10	NULL
,	NULL
13	NULL
,	NULL
18	NULL
,	NULL
25	NULL
Consensus	NULL
WW	NULL
Piss-Q130	NULL
Rigs	NULL
!	NULL

5	NULL
,	NULL
*	NULL
8,2	NULL
24,2	NULL
16,4	NULL
17	NULL
,	NULL
*	NULL
20¢	NULL
WwW	NULL
Pis	NULL
0130-Risgs	NULL
2	NULL
AO	NULL
P1.48-01-30-R4.9-P22.68-01-30-Ries	NULL
JC	NULL
12	NULL
Consensus	NULL
CY	NULL
25bp-23bp-55bp-66bp-18bp-69bp	NULL
!	NULL

14	NULL
,	NULL
*	NULL
23	NULL
%	NULL
CY	NULL
25bp-23bp-55bp-66bp-18bp-69bp	NULL
*From	NULL
patient	NULL
9	NULL
,	NULL
no	NULL
sequence	NULL
was	NULL
obtained	NULL
.	NULL

*For	NULL
these	NULL
patients	NULL
,	NULL
the	NULL
NCCRs	NULL
contained	NULL
point	NULL
mutations	NULL
compared	NULL
to	NULL
the	NULL
consensus	NULL
sequence	NULL
of	NULL
BKV	NULL
(	NULL
WW	NULL
)	NULL
or	NULL
JCV	NULL
(	NULL
CY	NULL
)	NULL
,	NULL
respectively	NULL
(	NULL
A.	NULL
Sundsfjord	NULL
et	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

'The	NULL
BKV	NULL
NCCR	NULL
is	NULL
divided	NULL
into	NULL
P-	NULL
,	NULL
Q-	NULL
,	NULL
and	NULL
R-blocks	NULL
.	NULL

They	NULL
consist	NULL
of	NULL
68	NULL
,	NULL
39	NULL
,	NULL
and	NULL
63	NULL
base	NULL
pairs	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
lower	NULL
case	NULL
numbers	NULL
represent	NULL
the	NULL
borders	NULL
of	NULL
each	NULL
block	NULL
.	NULL

``	NULL
The	NULL
JCV	NULL
NCCR	NULL
is	NULL
divided	NULL
into	NULL
blocks	NULL
ac	NULL
cording	NULL
to	NULL
the	NULL
number	NULL
of	NULL
base	NULL
pairs	NULL
.	NULL

2048	NULL
-	NULL
Rekvig	NULL
et	NULL
al	NULL
.	NULL

Group	NULL
|	NULL
_	NULL
sie11	NULL
SLE19	NULL
o	NULL
E	NULL
$	NULL
100	NULL
%	NULL
4	NULL
100	NULL
%	NULL
a	NULL
€	NULL
doa	NULL
.	NULL

wae	NULL
-	NULL
ct	NULL
«	NULL
~	NULL
£	NULL
59	NULL
#	NULL
7	NULL
som	NULL
``	NULL
=-	NULL
*~	NULL
**	NULL
Nal	NULL
je	NULL
*T	NULL
3	NULL
&	NULL
.	NULL

~~	NULL
fon	NULL
.	NULL

H	NULL
OE	NULL
0	NULL
%	NULL
+	NULL
--	NULL
-	NULL
r	NULL
096mm	NULL
Fi	NULL
2	NULL
.	NULL

Pol	NULL
©	NULL
tivati	NULL
o	NULL
4008	NULL
g2	NULL
1821	NULL
24	NULL
28	NULL
0	NULL
34	NULL
a1	NULL
00	NULL
4	NULL
08	NULL
42	NULL
16	NULL
200	NULL
24	NULL
280	NULL
320	NULL
36	NULL
igure	NULL
2	NULL
.	NULL

Polyomavirus	NULL
reactivation	NULL
POR	NULL
:	NULL
-	NULL
L	NULL
2	NULL
°	NULL
c	NULL
-	NULL
oo	NULL
and	NULL
immune	NULL
responses	NULL
to	NULL
T-ag	NULL
and	NULL
(	NULL
T-ag/NCCR	NULL
)	NULL
DNA	NULL
in	NULL
human	NULL
SLE	NULL
.	NULL

Antibody	NULL
activities	NULL
against	NULL
CT	NULL
DNA	NULL
(	NULL
-+-	NULL
)	NULL
and	NULL
polyomavirus	NULL
T-ag	NULL
(	NULL
-B-	NULL
)	NULL
at	NULL
the	NULL
Group	NULL
II	NULL
ste13	NULL
Group	NULL
III	NULL
ste	NULL
4	NULL
given	NULL
time	NULL
points	NULL
are	NULL
plotted	NULL
against	NULL
70	NULL
%	NULL
results	NULL
from	NULL
PCR-amplified	NULL
urine	NULL
P	NULL
50	NULL
%	NULL
samples	NULL
using	NULL
primers	NULL
complemen-	NULL
0	NULL
%	NULL
tary	NULL
to	NULL
NCCR	NULL
and	NULL
T-ag-encoding	NULL
polyomavirus	NULL
DNA	NULL
(	NULL
+	NULL
:	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
;	NULL
-	NULL
:	NULL
PCR-negative	NULL
urine	NULL
samples	NULL
)	NULL
.	NULL

ELISA	NULL
results	NULL
0	NULL
0	NULL
4	NULL
8	NULL
14	NULL
18	NULL
23	NULL
28	NULL
82	NULL
36	NULL
42	NULL
46	NULL
p	NULL
4	NULL
s	NULL
iz	NULL
16	NULL
2225	NULL
29	NULL
ss	NULL
37	NULL
41	NULL
45	NULL
are	NULL
presented	NULL
at	NULL
nonsaturating	NULL
se-PCR1	NULL
2	NULL
24k	NULL
20	NULL
2	NULL
2	NULL
~~	NULL
hone	NULL
2	NULL
2	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
e	NULL
>	NULL
2	NULL
ue	NULL
Wth	NULL
FFu	NULL
ae	NULL
2k	NULL
2	NULL
e	NULL
ech	NULL
s	NULL
Peel	NULL
atura	NULL
(	NULL
T-ag/NCCBR	NULL
)	NULL
rum	NULL
dilutions	NULL
for	NULL
the	NULL
individual	NULL
pa	NULL
Group	NULL
IV	NULL
sLes	NULL
2	NULL
a	NULL
100	NULL
%	NULL
,	NULL
258	NULL
_	NULL
fe-	NULL
ig	NULL
e	NULL
alo	NULL
©	NULL
E	NULL
640g	NULL
2	NULL
|	NULL
/	NULL
he	NULL
}	NULL
g	NULL
§	NULL
50	NULL
%	NULL
«	NULL
[	NULL
4	NULL
t	NULL
-	NULL
€	NULL
Tq	NULL
L_	NULL
3	NULL
16	NULL
E	NULL
E	NULL
6	NULL
o	NULL
E	NULL
G.	NULL
8	NULL
3	NULL
4a	NULL
$	NULL
|-®	NULL
_	NULL
goo	NULL
0.2	NULL
0	NULL
4	NULL
8	NULL
1216	NULL
_	NULL
24	NULL
2731	NULL
-	NULL
38	NULL
42	NULL
48	NULL
160	NULL
PCR	NULL
:	NULL
+++	NULL
O+	NULL
4+4+4+	NULL
+44	NULL
--	NULL
(	NULL
T-ag/NCCBR	NULL
)	NULL
|	NULL
--	NULL
weeks	NULL
_	NULL
___	NULL
gz	NULL
.	NULL

Anti-T-ag	NULL
antibodies	NULL
related	NULL
to	NULL
detection	NULL
of	NULL
viral	NULL
DNA	NULL
sequences	NULL
in	NULL
urine	NULL
samples	NULL
from	NULL
SLE	NULL
.	NULL

Detection	NULL
of	NULL
polyomavirus	NULL
DNA	NULL
corresponding	NULL
to	NULL
T-ag	NULL
encoding	NULL
sequences	NULL
by	NULL
PCR	NULL
did	NULL
not	NULL
prove	NULL
the	NULL
expression	NULL
of	NULL
large	NULL
T-ag	NULL
,	NULL
which	NULL
is	NULL
considered	NULL
essential	NULL
for	NULL
rendering	NULL
DNA	NULL
immunogenic	NULL
(	NULL
14	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
serial	NULL
serum	NULL
samples	NULL
from	NULL
each	NULL
SLE	NULL
patient	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
,	NULL
an	NULL
indication	NULL
of	NULL
T-ag	NULL
expression	NULL
.	NULL

These	NULL
antibodies	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
any	NULL
serum	NULL
sample	NULL
from	NULL
patients	NULL
in	NULL
group	NULL
I	NULL
(	NULL
Table	NULL
II	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
for	NULL
patients	NULL
11	NULL
and	NULL
19	NULL
)	NULL
.	NULL

In	NULL
sera	NULL
of	NULL
patients	NULL
of	NULL
group	NULL
II	NULL
,	NULL
weak	NULL
and	NULL
transient	NULL
anti-T-ag	NULL
antibody	NULL
response	NULL
was	NULL
detected	NULL
in	NULL
patient	NULL
13	NULL
(	NULL
Table	NULL
II	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
preceded	NULL
by	NULL
the	NULL
single	NULL
episode	NULL
of	NULL
virus	NULL
reactivation	NULL
.	NULL

A	NULL
similar	NULL
result	NULL
was	NULL
also	NULL
obtained	NULL
for	NULL
patient	NULL
9	NULL
,	NULL
although	NULL
critical	NULL
serum	NULL
samples	NULL
were	NULL
missing	NULL
for	NULL
this	NULL
patient	NULL
.	NULL

The	NULL
last	NULL
negative	NULL
sample	NULL
(	NULL
drawn	NULL
at	NULL
week	NULL
16	NULL
)	NULL
,	NULL
however	NULL
,	NULL
preceding	NULL
the	NULL
PCR-positive	NULL
serum	NULL
sample	NULL
(	NULL
week	NULL
22	NULL
)	NULL
,	NULL
was	NULL
followed	NULL
by	NULL
a	NULL
serum	NULL
sample	NULL
at	NULL
week	NULL
28	NULL
positive	NULL
for	NULL
anti-T-ag	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
course	NULL
of	NULL
this	NULL
response	NULL
could	NULL
not	NULL
be	NULL
determined	NULL
for	NULL
this	NULL
patient	NULL
as	NULL
the	NULL
single	NULL
PCR-positive	NULL
urine	NULL
sample	NULL
appeared	NULL
near	NULL
the	NULL
end	NULL
of	NULL
the	NULL
observation	NULL
time	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
patient	NULL
13	NULL
,	NULL
and	NULL
also	NULL
possibly	NULL
for	NULL
patient	NULL
9	NULL
,	NULL
we	NULL
could	NULL
directly	NULL
determine	NULL
an	NULL
anti-T-ag	NULL
antibody	NULL
response	NULL
preceded	NULL
by	NULL
a	NULL
single	NULL
episode	NULL
of	NULL
polyomavirus	NULL
reactivation	NULL
.	NULL

Both	NULL
patients	NULL
in	NULL
group	NULL
III	NULL
had	NULL
similar	NULL
anti-T-ag	NULL
responses	NULL
(	NULL
Table	NULL
II	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
for	NULL
patient	NULL
4	NULL
)	NULL
connected	NULL
in	NULL
time	NULL
to	NULL
the	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
.	NULL

For	NULL
patient	NULL
4	NULL
,	NULL
the	NULL
anti-T-ag	NULL
response	NULL
tient	NULL
;	NULL
binding	NULL
values	NULL
are	NULL
given	NULL
as	NULL
%	NULL
of	NULL
maximum	NULL
binding	NULL
of	NULL
reference	NULL
antibodies	NULL
.	NULL

The	NULL
ELISA	NULL
results	NULL
are	NULL
given	NULL
at	NULL
serum	NULL
dilution	NULL
1/100	NULL
for	NULL
patient	NULL
11	NULL
,	NULL
1/200	NULL
for	NULL
patients	NULL
13	NULL
and	NULL
4	NULL
,	NULL
1/500	NULL
for	NULL
patient	NULL
19	NULL
,	NULL
and	NULL
1/1000	NULL
for	NULL
patient	NULL
5	NULL
.	NULL

For	NULL
mean	NULL
titers	NULL
of	NULL
the	NULL
antibodies	NULL
for	NULL
the	NULL
individual	NULL
patients	NULL
,	NULL
see	NULL
Table	NULL
II	NULL
.	NULL

The	NULL
twofold	NULL
dilution	NULL
curves	NULL
for	NULL
the	NULL
reference	NULL
serum	NULL
used	NULL
for	NULL
determination	NULL
of	NULL
titers	NULL
of	NULL
the	NULL
individual	NULL
antibodies	NULL
is	NULL
presented	NULL
in	NULL
the	NULL
lower	NULL
right	NULL
panel	NULL
.	NULL

The	NULL
bars	NULL
in	NULL
the	NULL
figure	NULL
for	NULL
patient	NULL
5	NULL
represent	NULL
titers	NULL
in	NULL
the	NULL
Crithidia	NULL
luciliae	NULL
test	NULL
for	NULL
this	NULL
patient	NULL
.	NULL

m	NULL
T-ag	NULL
#	NULL
CT	NULL
DNA	NULL
&	NULL
Albumin	NULL
400	NULL
1600	NULL
6400	NULL
26500	NULL
2-fold	NULL
dilution	NULL
of	NULL
positive	NULL
reference	NULL
antibodies	NULL
fluctuated	NULL
above	NULL
the	NULL
baseline	NULL
(	NULL
mean	NULL
titer	NULL
for	NULL
the	NULL
observation	NULL
period	NULL
was	NULL
217	NULL
)	NULL
,	NULL
and	NULL
the	NULL
titer	NULL
increased	NULL
following	NULL
episodes	NULL
of	NULL
viral	NULL
DNA	NULL
shedding	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
,	NULL
however	NULL
less	NULL
distinct	NULL
because	NULL
of	NULL
weak	NULL
anti-T-ag	NULL
antibodies	NULL
was	NULL
observed	NULL
for	NULL
patient	NULL
2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

For	NULL
the	NULL
remaining	NULL
12	NULL
patients	NULL
(	NULL
group	NULL
IV	NULL
)	NULL
,	NULL
strong	NULL
and	NULL
persistent	NULL
production	NULL
of	NULL
antibodies	NULL
to	NULL
the	NULL
T-ag	NULL
,	NULL
with	NULL
mean	NULL
titers	NULL
ranging	NULL
from	NULL
315	NULL
to	NULL
854	NULL
,	NULL
was	NULL
recorded	NULL
(	NULL
Table	NULL
II	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
for	NULL
patient	NULL
5	NULL
)	NULL
.	NULL

These	NULL
data	NULL
argue	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
T-ag	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
these	NULL
data	NULL
,	NULL
there	NULL
was	NULL
a	NULL
strong	NULL
positive	NULL
correlation	NULL
between	NULL
frequencies	NULL
of	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
and	NULL
mean	NULL
titers	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
,	NULL
r	NULL
=	NULL
0.86	NULL
,	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
there	NULL
was	NULL
an	NULL
inverse	NULL
relationship	NULL
between	NULL
the	NULL
frequency	NULL
of	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
and	NULL
coefficient	NULL
of	NULL
variance	NULL
(	NULL
CV	NULL
)	NULL
of	NULL
the	NULL
anti-T-ag	NULL
titers	NULL
in	NULL
individual	NULL
patients	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
idea	NULL
that	NULL
T-ag	NULL
expression	NULL
induced	NULL
this	NULL
antibody	NULL
in	NULL
vivo	NULL
.	NULL

Thus	NULL
,	NULL
frequent	NULL
or	NULL
persistent	NULL
expression	NULL
of	NULL
the	NULL
T-ag	NULL
resulted	NULL
in	NULL
high	NULL
and	NULL
stable	NULL
titers	NULL
(	NULL
as	NULL
demonstrated	NULL
by	NULL
low	NULL
CV	NULL
)	NULL
of	NULL
the	NULL
anti-T-ag	NULL
antibodies	NULL
,	NULL
as	NULL
expected	NULL
for	NULL
an	NULL
antibody	NULL
induced	NULL
by	NULL
an	NULL
acquired	NULL
nonself	NULL
antigen	NULL
like	NULL
the	NULL
T-ag	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
polyomavirus	NULL
DNA	NULL
shedding	NULL
,	NULL
anti-T	NULL
-ag	NULL
antibodies	NULL
,	NULL
and	NULL
development	NULL
of	NULL
anti-DNA	NULL
antibodies	NULL
in	NULL
SLE	NULL
patients	NULL
.	NULL

In	NULL
group	NULL
I	NULL
,	NULL
anti-DNA	NULL
antibodies	NULL
could	NULL
not	NULL
be	NULL
detected	NULL
for	NULL
patients	NULL
7	NULL
,	NULL
11	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
,	NULL
and	NULL
21	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

For	NULL
Polyomaviruses	NULL
and	NULL
Autoimmunity	NULL
to	NULL
DNA	NULL
in	NULL
SLE	NULL
__	NULL
2049	NULL
patient	NULL
19	NULL
,	NULL
however	NULL
,	NULL
strong	NULL
and	NULL
persistent	NULL
anti-ssDNA	NULL
response	NULL
was	NULL
observed	NULL
,	NULL
with	NULL
titers	NULL
ranging	NULL
from	NULL
590	NULL
to	NULL
920	NULL
,	NULL
mean	NULL
titer	NULL
758	NULL
(	NULL
Table	NULL
II	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

For	NULL
both	NULL
patients	NULL
in	NULL
group	NULL
II	NULL
,	NULL
antibodies	NULL
to	NULL
ssDNA	NULL
were	NULL
detected	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

In	NULL
patient	NULL
13	NULL
,	NULL
the	NULL
virus	NULL
reactivation	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
combined	NULL
detection	NULL
of	NULL
single	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
and	NULL
subsequent	NULL
development	NULL
of	NULL
antibodies	NULL
to	NULL
T-ag	NULL
,	NULL
preceded	NULL
the	NULL
transient	NULL
production	NULL
of	NULL
antibodies	NULL
to	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
patient	NULL
9	NULL
,	NULL
antibodies	NULL
to	NULL
ssDNA	NULL
increased	NULL
simultaneously	NULL
with	NULL
antibodies	NULL
to	NULL
T-ag	NULL
after	NULL
the	NULL
single	NULL
PCR-positive	NULL
urine	NULL
sample	NULL
appearing	NULL
near	NULL
the	NULL
end	NULL
of	NULL
the	NULL
observation	NULL
period	NULL
.	NULL

The	NULL
course	NULL
of	NULL
this	NULL
response	NULL
could	NULL
not	NULL
be	NULL
deter-mined	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
for	NULL
patients	NULL
2	NULL
and	NULL
4	NULL
in	NULL
group	NULL
III	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
for	NULL
these	NULL
patients	NULL
,	NULL
production	NULL
of	NULL
antibodies	NULL
to	NULL
ssDNA	NULL
were	NULL
related	NULL
in	NULL
time	NULL
to	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
,	NULL
and	NULL
to	NULL
the	NULL
development	NULL
of	NULL
antibodies	NULL
to	NULL
T-ag	NULL
with	NULL
mean	NULL
antiDNA	NULL
titers	NULL
of	NULL
11	NULL
(	NULL
ranging	NULL
from	NULL
0-100	NULL
)	NULL
and	NULL
146	NULL
(	NULL
ranging	NULL
from	NULL
100-190	NULL
)	NULL
for	NULL
patients	NULL
2	NULL
and	NULL
4	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
II	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
patient	NULL
4	NULL
)	NULL
.	NULL

For	NULL
patients	NULL
in	NULL
group	NULL
IV	NULL
,	NULL
anti-ssDNA	NULL
antibodies	NULL
persisted	NULL
at	NULL
high	NULL
levels	NULL
throughout	NULL
the	NULL
observation	NULL
period	NULL
,	NULL
with	NULL
mean	NULL
titers	NULL
ranging	NULL
from	NULL
207	NULL
to	NULL
956	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
,	NULL
similar	NULL
to	NULL
those	NULL
observed	NULL
for	NULL
anti-T-ag	NULL
antibodies	NULL
.	NULL

Patients	NULL
5	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
and	NULL
20	NULL
produced	NULL
anti-dsDNA	NULL
antibodies	NULL
detectable	NULL
by	NULL
the	NULL
Crithidia	NULL
luciliae	NULL
assay	NULL
,	NULL
with	NULL
mean	NULL
Crithidia	NULL
titers	NULL
of	NULL
64	NULL
,	NULL
33	NULL
,	NULL
20	NULL
,	NULL
and	NULL
67	NULL
,	NULL
respectively	NULL
,	NULL
over	NULL
the	NULL
observation	NULL
time	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
for	NULL
patient	NULL
5	NULL
)	NULL
.	NULL

These	NULL
,	NULL
and	NULL
three	NULL
additional	NULL
patients	NULL
(	NULL
16	NULL
,	NULL
17	NULL
,	NULL
and	NULL
25	NULL
)	NULL
in	NULL
group	NULL
IV	NULL
produced	NULL
anti-dsDNA	NULL
antibodies	NULL
detectable	NULL
in	NULL
an	NULL
ELISA	NULL
specific	NULL
for	NULL
dsDNA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
except	NULL
for	NULL
patient	NULL
19	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
anti-DNA	NULL
antibodies	NULL
was	NULL
limited	NULL
to	NULL
patients	NULL
shedding	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
in	NULL
their	NULL
urine	NULL
,	NULL
while	NULL
antibodies	NULL
with	NULL
specificity	NULL
for	NULL
dsDNA	NULL
were	NULL
restricted	NULL
to	NULL
group	NULL
IV	NULL
patients	NULL
.	NULL

2050	NULL
_	NULL
Rekvig	NULL
et	NULL
al	NULL
.	NULL

A	NULL
B	NULL
900	NULL
1000	NULL
800	NULL
900	NULL
700	NULL
_	NULL
800	NULL
3	NULL
soo	NULL
£	NULL
100	NULL
g	NULL
500	NULL
3	NULL
222	NULL
£	NULL
.	NULL

400	NULL
a	NULL
a00	NULL
&	NULL
30	NULL
3	NULL
200	NULL
200	NULL
<	NULL
200	NULL
100	NULL
100	NULL
0	NULL
0	NULL
o	NULL
20	NULL
40	NULL
60	NULL
so	NULL
100	NULL
%	NULL
PCR	NULL
%	NULL
PCR	NULL
C	NULL
D	NULL
1200	NULL
1400	NULL
Figure	NULL
3	NULL
.	NULL

Anti-T-ag	NULL
and	NULL
anti-DNA	NULL
antibody	NULL
1000	NULL
r=0.604	NULL
=	NULL
1200	NULL
titers	NULL
and	NULL
'their	NULL
corrélations	NULL
with	NULL
frequency	NULL
of	NULL
g	NULL
T	NULL
1000	NULL
polyomawruhs	NULL
reactlyatlons	NULL
in	NULL
hl'lman	NULL
SLE	NULL
.	NULL
'	NULL

a	NULL
soo	NULL
®	NULL
g	NULL
Mean	NULL
of	NULL
anti-T-ag	NULL
titer	NULL
(	NULL
A	NULL
)	NULL
,	NULL
anti-ssDNA	NULL
titer	NULL
o	NULL
<	NULL
800	NULL
(	NULL
B	NULL
)	NULL
,	NULL
OD	NULL
492	NULL
of	NULL
serum	NULL
antibody	NULL
binding	NULL
to	NULL
g	NULL
600	NULL
a	NULL
e00	NULL
CT	NULL
dsDNA	NULL
at	NULL
a	NULL
1/100	NULL
dilution	NULL
(	NULL
cutoff	NULL
value	NULL
8	NULL
aco	NULL
é	NULL
400	NULL
was	NULL
0.2	NULL
OD	NULL
units	NULL
)	NULL
(	NULL
C	NULL
)	NULL
over	NULL
the	NULL
observation	NULL
3	NULL
<	NULL
time	NULL
plotted	NULL
against	NULL
the	NULL
frequency	NULL
of	NULL
PCR	NULL
am-C	NULL
200	NULL
200	NULL
plified	NULL
urine	NULL
samples	NULL
for	NULL
each	NULL
individual	NULL
pa-o	NULL
o	NULL
4	NULL
4	NULL
tient	NULL
.	NULL

In	NULL
D	NULL
,	NULL
correlation	NULL
between	NULL
anti-T-ag	NULL
and	NULL
o	NULL
500	NULL
1000	NULL
1500	NULL
anti-DNA	NULL
antibody	NULL
titers	NULL
at	NULL
all	NULL
time	NULL
points	NULL
for	NULL
Anti-T-ag	NULL
(	NULL
titer	NULL
)	NULL
all	NULL
patients	NULL
are	NULL
given	NULL
.	NULL

The	NULL
correlation	NULL
coefficient	NULL
(	NULL
r	NULL
)	NULL
is	NULL
indicated	NULL
in	NULL
each	NULL
figure	NULL
.	NULL

As	NULL
for	NULL
anti-T-ag	NULL
antibodies	NULL
,	NULL
the	NULL
mean	NULL
anti-ssDNA	NULL
titers	NULL
correlated	NULL
strongly	NULL
with	NULL
the	NULL
frequency	NULL
of	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
,	NULL
r	NULL
=	NULL
0.747	NULL
,	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

An	NULL
inverse	NULL
correlation	NULL
between	NULL
this	NULL
frequency	NULL
and	NULL
CV	NULL
of	NULL
the	NULL
mean	NULL
anti-ssDNA	NULL
titers	NULL
was	NULL
also	NULL
established	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
recurrent	NULL
PCR-positive	NULL
urine	NULL
samples	NULL
within	NULL
single	NULL
individuals	NULL
of	NULL
group	NULL
IV	NULL
reflect	NULL
recurrent	NULL
stimulation	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
consistent	NULL
with	NULL
high	NULL
and	NULL
stable	NULL
anti-DNA	NULL
antibody	NULL
titers	NULL
.	NULL

This	NULL
,	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
there	NULL
was	NULL
a	NULL
strong	NULL
positive	NULL
correlation	NULL
between	NULL
anti-T-ag	NULL
and	NULL
anti-ss	NULL
DNA	NULL
antibody	NULL
titers	NULL
in	NULL
all	NULL
patients	NULL
at	NULL
all	NULL
time	NULL
points	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
D	NULL
,	NULL
r	NULL
=	NULL
0.733	NULL
,	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
,	NULL
strongly	NULL
indicate	NULL
that	NULL
anti-DNA	NULL
antibodies	NULL
,	NULL
as	NULL
antibodies	NULL
to	NULL
the	NULL
T-ag	NULL
,	NULL
are	NULL
induced	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
T-ag	NULL
expression	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
strength	NULL
of	NULL
anti-dsDNA	NULL
also	NULL
increased	NULL
with	NULL
increasing	NULL
frequency	NULL
of	NULL
polyomavirus	NULL
reactivation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
,	NULL
r	NULL
=	NULL
0.60	NULL
)	NULL
,	NULL
and	NULL
there	NULL
was	NULL
a	NULL
significant	NULL
correlation	NULL
between	NULL
anti-dsDNA	NULL
antibodies	NULL
and	NULL
their	NULL
presence	NULL
in	NULL
group	NULL
IV	NULL
patients	NULL
(	NULL
x2	NULL
=	NULL
7.18	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
RF	NULL
in	NULL
these	NULL
patients	NULL
did	NULL
not	NULL
correlate	NULL
with	NULL
polyomavirus	NULL
reactivations	NULL
,	NULL
nor	NULL
with	NULL
presence	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
from	NULL
the	NULL
following	NULL
observations	NULL
.	NULL

Only	NULL
four	NULL
of	NULL
the	NULL
20	NULL
patients	NULL
produced	NULL
this	NULL
autoantibody	NULL
(	NULL
patient	NULL
21	NULL
in	NULL
group	NULL
I	NULL
,	NULL
and	NULL
patients	NULL
8	NULL
,	NULL
16	NULL
and	NULL
23	NULL
in	NULL
group	NULL
IV	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
9	NULL
out	NULL
of	NULL
the	NULL
12	NULL
patients	NULL
in	NULL
group	NULL
IV	NULL
,	NULL
and	NULL
in	NULL
all	NULL
patients	NULL
belonging	NULL
to	NULL
group	NULL
II	NULL
or	NULL
III	NULL
,	NULL
RF	NULL
was	NULL
not	NULL
detected	NULL
.	NULL

Among	NULL
112	NULL
other	NULL
sera	NULL
from	NULL
autoimmune	NULL
patients	NULL
(	NULL
RA	NULL
,	NULL
Sjggren	NULL
syndrome	NULL
,	NULL
and	NULL
SLE	NULL
)	NULL
,	NULL
39	NULL
contained	NULL
antibodies	NULL
to	NULL
T-ag	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
8	NULL
(	NULL
21	NULL
%	NULL
)	NULL
were	NULL
positive	NULL
for	NULL
RF	NULL
,	NULL
while	NULL
17	NULL
out	NULL
of	NULL
the	NULL
73	NULL
anti-T-ag	NULL
negative	NULL
sera	NULL
(	NULL
23	NULL
%	NULL
)	NULL
contained	NULL
RF	NULL
(	NULL
r	NULL
=	NULL
0.035	NULL
,	NULL
P	NULL
>	NULL
0.5	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
TBP	NULL
and	NULL
CREB	NULL
.	NULL

Because	NULL
of	NULL
small	NULL
available	NULL
amounts	NULL
of	NULL
TBP	NULL
and	NULL
CREB	NULL
molecules	NULL
,	NULL
only	NULL
sera	NULL
with	NULL
the	NULL
highest	NULL
levels	NULL
of	NULL
anti-T-ag	NULL
and	NULL
anti-DNA	NULL
activities	NULL
,	NULL
together	NULL
with	NULL
randomly	NULL
selected	NULL
sera	NULL
from	NULL
SLE	NULL
group	NULL
I	NULL
,	NULL
were	NULL
tested	NULL
for	NULL
antibodies	NULL
against	NULL
the	NULL
transcription	NULL
factors	NULL
TBP	NULL
and	NULL
CREB	NULL
.	NULL

A	NULL
©	NULL
18600	NULL
6	NULL
3	NULL
1400	NULL
5	NULL
.	NULL

S	NULL
1200	NULL
@	NULL
g	NULL
a	NULL
&	NULL
1000	NULL
4	NULL
$	NULL
|	NULL
e	NULL
#	NULL
C	NULL
soo	NULL
.	NULL

*	NULL
®	NULL
E	NULL
[	NULL
=	NULL
)	NULL
]	NULL
*	NULL
e	NULL
e	NULL
_	NULL
*	NULL
3	NULL
2	NULL
600	NULL
h	NULL
e®	NULL
&	NULL
L	NULL
©	NULL
-_	NULL
400	NULL
o	NULL
O	NULL
.	NULL

2	NULL
-	NULL
200	NULL
%	NULL
go	NULL
©	NULL
0°	NULL
p	NULL
,	NULL
E	NULL
0	NULL
4	NULL
t	NULL
t	NULL
1	NULL
0	NULL
500	NULL
1000	NULL
1500	NULL
Anti-T-ag	NULL
(	NULL
titer	NULL
)	NULL
1800	NULL
B	NULL
#	NULL
1600	NULL
J	NULL
®	NULL
t	NULL
8	NULL
,	NULL
1400	NULL
m	NULL
a	NULL
m	NULL
w	NULL
1200	NULL
%	NULL
'	NULL
!	NULL

1	NULL
.	NULL
'	NULL

l	NULL
a	NULL
9	NULL
1000	NULL
m	NULL
E	NULL
H	NULL
E	NULL
800	NULL
%	NULL
a	NULL
m	NULL
-	NULL
600	NULL
J	NULL
@	NULL
m	NULL
ip	NULL
a	NULL
&	NULL
400	NULL
3	NULL
200	NULL
2	NULL
<	NULL
4	NULL
0	NULL
4	NULL
+	NULL
a	NULL
A4	NULL
0	NULL
500	NULL
1000	NULL
1500	NULL
Anti-T-ag	NULL
(	NULL
titer	NULL
)	NULL
SLE	NULL
9	NULL
SLE	NULL
13	NULL
C	NULL
2000	NULL
«	NULL
»	NULL
(	NULL
w	NULL
10	NULL
)	NULL
(	NULL
w	NULL
28	NULL
)	NULL
(	NULL
w	NULL
4	NULL
)	NULL
m	NULL
(	NULL
w	NULL
8	NULL
)	NULL
\	NULL
1500	NULL
\	NULL
a	NULL
e	NULL
&	NULL
%	NULL
1000	NULL
\	NULL
.	NULL
'	NULL

3	NULL
\	NULL
\\	NULL
ne	NULL
‘	NULL
\\	NULL
500	NULL
Ce	NULL
”	NULL
a	NULL
O	NULL
o	NULL
o	NULL
o	NULL
l=	NULL
=	NULL
]	NULL
o	NULL
O	NULL
O	NULL
o	NULL
o	NULL
O	NULL
O	NULL
l=	NULL
]	NULL
[	NULL
«	NULL
]	NULL
o	NULL
«	NULL
-	NULL
A-	NULL
«	NULL
-	NULL
QL	NULL
-	NULL
OA	NULL
C	NULL
)	NULL
C	NULL
el	NULL
C	NULL
)	NULL
2-fold	NULL
serum	NULL
dilutions	NULL
Figure	NULL
4	NULL
.	NULL

Serum	NULL
antibodies	NULL
to	NULL
TBP	NULL
(	NULL
@	NULL
)	NULL
and	NULL
GST	NULL
(	NULL
O0	NULL
)	NULL
,	NULL
(	NULL
A4	NULL
)	NULL
and	NULL
CREB	NULL
(	NULL
M	NULL
,	NULL
3	NULL
)	NULL
are	NULL
plotted	NULL
against	NULL
titers	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
in	NULL
selected	NULL
sera	NULL
from	NULL
individual	NULL
SLE	NULL
patients	NULL
.	NULL

The	NULL
binding	NULL
values	NULL
(	NULL
OD	NULL
492	NULL
)	NULL
for	NULL
antibodies	NULL
to	NULL
TBP	NULL
and	NULL
CREB	NULL
are	NULL
given	NULL
at	NULL
nonsaturating	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
1/200	NULL
)	NULL
dilutions	NULL
of	NULL
the	NULL
sera	NULL
.	NULL

For	NULL
patients	NULL
9	NULL
and	NULL
13	NULL
(	NULL
group	NULL
II	NULL
)	NULL
,	NULL
serum	NULL
antibodies	NULL
to	NULL
TBP	NULL
(	NULL
@	NULL
)	NULL
and	NULL
CREB	NULL
(	NULL
)	NULL
before	NULL
and	NULL
after	NULL
the	NULL
single	NULL
polyomavirus	NULL
reactivations	NULL
are	NULL
demonstrated	NULL
.	NULL

Binding	NULL
values	NULL
are	NULL
given	NULL
as	NULL
OD	NULL
492	NULL
at	NULL
twofold	NULL
serum	NULL
dilutions	NULL
from	NULL
1/100	NULL
to	NULL
1/3200	NULL
.	NULL

As	NULL
demonstrated	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
all	NULL
anti-T-ag	NULL
positive	NULL
sera	NULL
tested	NULL
from	NULL
groups	NULL
II-IV	NULL
(	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
serum	NULL
from	NULL
patient	NULL
19	NULL
of	NULL
group	NULL
I	NULL
)	NULL
were	NULL
positive	NULL
for	NULL
anti-TBP	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
4	NULL
)	NULL
and	NULL
anti-CREB	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
antibodies	NULL
.	NULL

In	NULL
sera	NULL
from	NULL
group	NULL
II	NULL
patients	NULL
(	NULL
9	NULL
and	NULL
13	NULL
)	NULL
drawn	NULL
before	NULL
the	NULL
virus	NULL
expression	NULL
episode	NULL
(	NULL
week	NULL
10	NULL
and	NULL
week	NULL
4	NULL
for	NULL
patients	NULL
9	NULL
and	NULL
13	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
no	NULL
or	NULL
weak	NULL
anti-TBP	NULL
and	NULL
anti-CREB	NULL
antibodies	NULL
were	NULL
detected	NULL
.	NULL

Sera	NULL
drawn	NULL
after	NULL
this	NULL
time	NULL
point	NULL
(	NULL
week	NULL
28	NULL
and	NULL
8	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
however	NULL
,	NULL
were	NULL
increasingly	NULL
positive	NULL
in	NULL
these	NULL
tests	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
indicate	NULL
that	NULL
antibodies	NULL
to	NULL
TBP	NULL
and	NULL
CREB	NULL
,	NULL
like	NULL
antibodies	NULL
to	NULL
DNA	NULL
,	NULL
were	NULL
initiated	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
T-ag	NULL
expression	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
all	NULL
preimmune	NULL
sera	NULL
from	NULL
plasmid-inoculated	NULL
mice	NULL
,	NULL
and	NULL
all	NULL
sera	NULL
of	NULL
group	NULL
II	NULL
patients	NULL
drawn	NULL
before	NULL
virus	NULL
reactivations	NULL
,	NULL
were	NULL
negative	NULL
in	NULL
the	NULL
TBP	NULL
and	NULL
CREB	NULL
ELISAs	NULL
.	NULL

Not	NULL
all	NULL
sera	NULL
contained	NULL
antibodies	NULL
to	NULL
TBP	NULL
and	NULL
CREB	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
sera	NULL
from	NULL
patients	NULL
7	NULL
,	NULL
11	NULL
,	NULL
21	NULL
of	NULL
group	NULL
I	NULL
)	NULL
,	NULL
and	NULL
10	NULL
sera	NULL
from	NULL
group	NULL
IV	NULL
patients	NULL
positive	NULL
for	NULL
such	NULL
antibodies	NULL
did	NULL
not	NULL
bind	NULL
in	NULL
an	NULL
ELISA	NULL
specific	NULL
for	NULL
GST	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
)	NULL
.	NULL

These	NULL
results	NULL
argue	NULL
against	NULL
binding	NULL
of	NULL
serum	NULL
antibodies	NULL
to	NULL
bacterial	NULL
proteins	NULL
contaminating	NULL
the	NULL
TBP	NULL
and	NULL
CREB	NULL
prepa-rations	NULL
,	NULL
since	NULL
this	NULL
GST	NULL
is	NULL
also	NULL
purified	NULL
from	NULL
E.	NULL
coli	NULL
.	NULL

Discussion	NULL
In	NULL
the	NULL
present	NULL
report	NULL
we	NULL
have	NULL
investigated	NULL
whether	NULL
polyomaviruses	NULL
have	NULL
,	NULL
in	NULL
a	NULL
natural	NULL
situation	NULL
,	NULL
an	NULL
ability	NULL
to	NULL
induce	NULL
antibodies	NULL
to	NULL
DNA	NULL
and	NULL
DNA-associated	NULL
self	NULL
proteins	NULL
similar	NULL
to	NULL
that	NULL
previously	NULL
observed	NULL
in	NULL
an	NULL
experimental	NULL
context	NULL
in	NULL
rabbits	NULL
or	NULL
mice	NULL
(	NULL
11-14	NULL
,	NULL
28	NULL
,	NULL
33	NULL
)	NULL
.	NULL

For	NULL
these	NULL
studies	NULL
,	NULL
we	NULL
have	NULL
taken	NULL
advantage	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
virtually	NULL
all	NULL
human	NULL
individuals	NULL
are	NULL
latently	NULL
infected	NULL
by	NULL
such	NULL
viruses	NULL
.	NULL

The	NULL
biological	NULL
requirement	NULL
for	NULL
polyomaviruses	NULL
to	NULL
reactivate	NULL
is	NULL
fulfilled	NULL
upon	NULL
in	NULL
vivo	NULL
expression	NULL
of	NULL
the	NULL
viral	NULL
transcription	NULL
factor	NULL
T-ag	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
expression	NULL
of	NULL
T-ag	NULL
is	NULL
sufficient	NULL
to	NULL
initiate	NULL
the	NULL
production	NULL
of	NULL
antibodies	NULL
to	NULL
DNA	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
extended	NULL
the	NULL
observations	NULL
on	NULL
the	NULL
immune	NULL
responses	NULL
to	NULL
T-ag	NULL
expression	NULL
in	NULL
mice	NULL
to	NULL
include	NULL
detection	NULL
of	NULL
antibodies	NULL
,	NULL
not	NULL
only	NULL
to	NULL
DNA	NULL
,	NULL
but	NULL
also	NULL
to	NULL
the	NULL
transcription	NULL
factors	NULL
TBP	NULL
and	NULL
CREB	NULL
.	NULL

The	NULL
TBP	NULL
and	NULL
TBP-associated	NULL
factors	NULL
form	NULL
the	NULL
multiprotein	NULL
complex	NULL
TFIID	NULL
,	NULL
which	NULL
is	NULL
part	NULL
of	NULL
the	NULL
transcription	NULL
preinitiation	NULL
complex	NULL
.	NULL

TBP	NULL
is	NULL
the	NULL
only	NULL
component	NULL
of	NULL
TFIID	NULL
that	NULL
binds	NULL
directly	NULL
to	NULL
the	NULL
TATA	NULL
box	NULL
of	NULL
DNA	NULL
(	NULL
18	NULL
)	NULL
.	NULL

TBP	NULL
is	NULL
expressed	NULL
in	NULL
all	NULL
cell	NULL
types	NULL
(	NULL
18	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
studies	NULL
have	NULL
also	NULL
demonstrated	NULL
that	NULL
TBP	NULL
can	NULL
interact	NULL
with	NULL
SV40	NULL
T-ag	NULL
by	NULL
direct	NULL
pro-tein-protein	NULL
interaction	NULL
(	NULL
34	NULL
)	NULL
.	NULL

CREB	NULL
proteins	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
belong	NULL
to	NULL
a	NULL
large	NULL
family	NULL
of	NULL
related	NULL
proteins	NULL
which	NULL
also	NULL
includes	NULL
the	NULL
CREMs	NULL
(	NULL
cAMP-response	NULL
element	NULL
modulators	NULL
)	NULL
and	NULL
the	NULL
ATFs	NULL
(	NULL
activating	NULL
transcription	NULL
factors	NULL
)	NULL
.	NULL

Genes	NULL
whose	NULL
expression	NULL
are	NULL
regulated	NULL
by	NULL
the	NULL
secondary	NULL
messenger	NULL
cAMP	NULL
often	NULL
contain	NULL
the	NULL
palindromic	NULL
consensus	NULL
sequence	NULL
GTGAC-GTCA	NULL
,	NULL
the	NULL
so-called	NULL
cAMP	NULL
response	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
.	NULL

The	NULL
CRE	NULL
binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
binds	NULL
constitutively	NULL
to	NULL
this	NULL
sequence	NULL
(	NULL
19	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
CREB	NULL
can	NULL
bind	NULL
T-ag	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
TBP	NULL
and	NULL
CREB	NULL
bind	NULL
directly	NULL
to	NULL
DNA	NULL
or	NULL
nucleosomes	NULL
(	NULL
18	NULL
,	NULL
34	NULL
)	NULL
.	NULL

It	NULL
was	NULL
therefore	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
if	NULL
T-ag	NULL
binds	NULL
DNA	NULL
or	NULL
nucleosomes	NULL
(	NULL
35	NULL
)	NULL
,	NULL
not	NULL
only	NULL
DNA	NULL
and	NULL
his-tones	NULL
(	NULL
14	NULL
)	NULL
,	NULL
but	NULL
also	NULL
DNA-associated	NULL
polypeptides	NULL
like	NULL
TBP	NULL
and	NULL
CREB	NULL
are	NULL
rendered	NULL
immunogenic	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
T-ag	NULL
expression	NULL
and	NULL
subsequent	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

In	NULL
mice	NULL
inoculated	NULL
with	NULL
the	NULL
plasmids	NULL
encoding	NULL
wild-type	NULL
T-ags	NULL
,	NULL
strong	NULL
immune	NULL
responses	NULL
to	NULL
T-ag	NULL
,	NULL
DNA	NULL
,	NULL
TBP	NULL
,	NULL
and	NULL
CREB	NULL
were	NULL
detected	NULL
.	NULL

Sera	NULL
from	NULL
mice	NULL
inoculated	NULL
with	NULL
the	NULL
mutant	NULL
T-ag-expressing	NULL
plasmid	NULL
contained	NULL
strong	NULL
antibodies	NULL
to	NULL
T-ag	NULL
and	NULL
to	NULL
TBP	NULL
,	NULL
while	NULL
the	NULL
responses	NULL
to	NULL
DNA	NULL
and	NULL
CREB	NULL
were	NULL
less	NULL
pronounced	NULL
.	NULL

This	NULL
mutant	NULL
T-ag	NULL
binds	NULL
only	NULL
weakly	NULL
in	NULL
a	NULL
sequence-unspecific	NULL
way	NULL
to	NULL
DNA	NULL
,	NULL
which	NULL
may	NULL
explain	NULL
the	NULL
weak	NULL
DNA	NULL
and	NULL
anti-CREB	NULL
responses	NULL
in	NULL
these	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
.	NULL

Polyomaviruses	NULL
and	NULL
Autoimmunity	NULL
to	NULL
DNA	NULL
in	NULL
SLE	NULL
__	NULL
2051	NULL
These	NULL
results	NULL
contrast	NULL
strikingly	NULL
with	NULL
the	NULL
results	NULL
for	NULL
induction	NULL
of	NULL
anti-T-ag	NULL
and	NULL
anti-TBP	NULL
antibodies	NULL
obtained	NULL
in	NULL
the	NULL
same	NULL
mice	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
mutant	NULL
T-ag	NULL
and	NULL
TBP	NULL
form	NULL
a	NULL
stable	NULL
complex	NULL
in	NULL
vivo	NULL
resulting	NULL
in	NULL
cognate	NULL
interaction	NULL
of	NULL
TBP	NULL
specific	NULL
B-cells	NULL
and	NULL
T-ag	NULL
specific	NULL
T-cells	NULL
.	NULL

These	NULL
observations	NULL
represented	NULL
the	NULL
rational	NULL
bases	NULL
for	NULL
the	NULL
present	NULL
investigations	NULL
designed	NULL
to	NULL
examine	NULL
the	NULL
extent	NULL
of	NULL
polyomavirus	NULL
reactivations	NULL
,	NULL
and	NULL
particularly	NULL
T-ag	NULL
expression	NULL
,	NULL
in	NULL
SLE	NULL
,	NULL
and	NULL
whether	NULL
such	NULL
reactivations	NULL
reflect	NULL
a	NULL
natural	NULL
biological	NULL
origin	NULL
for	NULL
initiation	NULL
of	NULL
antibodies	NULL
to	NULL
DNA	NULL
and	NULL
to	NULL
other	NULL
nucleosome-associated	NULL
antigens	NULL
.	NULL

A	NULL
prominent	NULL
observation	NULL
made	NULL
was	NULL
that	NULL
of	NULL
the	NULL
high	NULL
frequency	NULL
of	NULL
polyomavirus	NULL
reactivations	NULL
within	NULL
and	NULL
between	NULL
SLE	NULL
patients	NULL
.	NULL

The	NULL
NCCRs	NULL
detected	NULL
(	NULL
all	NULL
except	NULL
that	NULL
for	NULL
patient	NULL
2	NULL
)	NULL
belonged	NULL
to	NULL
the	NULL
archetypal	NULL
WW	NULL
or	NULL
CY	NULL
of	NULL
polyomavirus	NULL
BK	NULL
or	NULL
JC	NULL
,	NULL
respectively	NULL
,	NULL
found	NULL
among	NULL
normal	NULL
individuals	NULL
.	NULL

Neither	NULL
certain	NULL
NCCR	NULL
rearrangements	NULL
nor	NULL
administration	NULL
of	NULL
steroid	NULL
hormones	NULL
to	NULL
the	NULL
SLE	NULL
patients	NULL
(	NULL
see	NULL
results	NULL
)	NULL
could	NULL
therefore	NULL
explain	NULL
the	NULL
strong	NULL
tendency	NULL
for	NULL
virus	NULL
reactivations	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

The	NULL
linkage	NULL
between	NULL
viral	NULL
DNA	NULL
shedding	NULL
and	NULL
development	NULL
of	NULL
anti-T-ag	NULL
antibodies	NULL
strongly	NULL
indicated	NULL
that	NULL
T-ag	NULL
expression	NULL
had	NULL
taken	NULL
place	NULL
.	NULL

The	NULL
anti-T-ag	NULL
antibody	NULL
profiles	NULL
in	NULL
individual	NULL
SLE	NULL
patients	NULL
are	NULL
thus	NULL
representative	NULL
for	NULL
conventional	NULL
immune	NULL
responses	NULL
to	NULL
a	NULL
foreign	NULL
antigen	NULL
,	NULL
providing	NULL
the	NULL
ideal	NULL
situation	NULL
to	NULL
compare	NULL
directly	NULL
a	NULL
conventional	NULL
and	NULL
an	NULL
assumed	NULL
autoimmune	NULL
anti-DNA	NULL
response	NULL
,	NULL
both	NULL
induced	NULL
by	NULL
the	NULL
same	NULL
nucleosome-T-ag	NULL
complex	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Analyzing	NULL
the	NULL
production	NULL
of	NULL
anti-DNA	NULL
antibodies	NULL
in	NULL
individual	NULL
patients	NULL
demonstrated	NULL
the	NULL
validity	NULL
of	NULL
this	NULL
approach	NULL
.	NULL

Both	NULL
the	NULL
time	NULL
points	NULL
for	NULL
their	NULL
initiation	NULL
and	NULL
their	NULL
profiles	NULL
strongly	NULL
indicated	NULL
that	NULL
anti-T-ag	NULL
and	NULL
anti-DNA	NULL
antibody	NULL
populations	NULL
were	NULL
temporally	NULL
linked	NULL
to	NULL
each	NULL
other	NULL
and	NULL
to	NULL
polyomavirus	NULL
reactivations	NULL
for	NULL
these	NULL
patients	NULL
.	NULL

For	NULL
group	NULL
IV	NULL
patients	NULL
,	NULL
anti-T-ag	NULL
and	NULL
anti-ssDNA	NULL
antibodies	NULL
were	NULL
produced	NULL
persistently	NULL
and	NULL
at	NULL
significantly	NULL
higher	NULL
levels	NULL
than	NULL
for	NULL
group	NULL
II	NULL
and	NULL
group	NULL
III	NULL
patients	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
dsDNA	NULL
were	NULL
exclusively	NULL
detected	NULL
in	NULL
group	NULL
IV	NULL
patients	NULL
.	NULL

Although	NULL
there	NULL
were	NULL
individual	NULL
variations	NULL
in	NULL
titers	NULL
over	NULL
the	NULL
observation	NULL
time	NULL
,	NULL
a	NULL
significant	NULL
correlation	NULL
existed	NULL
between	NULL
the	NULL
production	NULL
of	NULL
anti-T-ag	NULL
and	NULL
anti-DNA	NULL
antibodies	NULL
in	NULL
all	NULL
patients	NULL
at	NULL
all	NULL
time	NULL
points	NULL
.	NULL

In	NULL
group	NULL
II	NULL
patients	NULL
,	NULL
we	NULL
could	NULL
directly	NULL
demonstrate	NULL
that	NULL
the	NULL
virus	NULL
reactivation	NULL
preceded	NULL
the	NULL
development	NULL
of	NULL
these	NULL
antibodies	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
therefore	NULL
indicate	NULL
a	NULL
causal	NULL
relationship	NULL
between	NULL
development	NULL
of	NULL
anti-ssDNA/dsDNA	NULL
antibodies	NULL
and	NULL
expression	NULL
of	NULL
T-ag	NULL
in	NULL
context	NULL
of	NULL
polyomavirus	NULL
reactivations	NULL
in	NULL
vivo	NULL
.	NULL

Polyomaviruses	NULL
infect	NULL
almost	NULL
100	NULL
%	NULL
of	NULL
the	NULL
human	NULL
population	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

After	NULL
primary	NULL
infection	NULL
,	NULL
the	NULL
virus	NULL
remains	NULL
silent	NULL
,	NULL
and	NULL
reactivations	NULL
of	NULL
polyomaviruses	NULL
seem	NULL
to	NULL
be	NULL
rare	NULL
events	NULL
in	NULL
normal	NULL
individuals	NULL
(	NULL
36-40	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
from	NULL
a	NULL
total	NULL
of	NULL
341	NULL
urine	NULL
samples	NULL
from	NULL
normal	NULL
individuals	NULL
,	NULL
or	NULL
from	NULL
individuals	NULL
before	NULL
transplantation	NULL
(	NULL
taken	NULL
from	NULL
references	NULL
36-40	NULL
,	NULL
and	NULL
92	NULL
urine	NULL
samples	NULL
from	NULL
this	NULL
study	NULL
)	NULL
,	NULL
polyomavirus	NULL
DNA	NULL
sequences	NULL
were	NULL
detected	NULL
in	NULL
seven	NULL
(	NULL
2.1	NULL
%	NULL
)	NULL
.	NULL

Anti-T-ag	NULL
antibodies	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
sera	NULL
of	NULL
11	NULL
out	NULL
of	NULL
1,240	NULL
cancer	NULL
patients	NULL
(	NULL
0.9	NULL
%	NULL
)	NULL
,	NULL
and	NULL
in	NULL
4	NULL
out	NULL
of	NULL
501	NULL
normal	NULL
control	NULL
sera	NULL
(	NULL
0.8	NULL
%	NULL
)	NULL
(	NULL
41	NULL
)	NULL
.	NULL

As	NULL
antibodies	NULL
to	NULL
T-ag	NULL
are	NULL
a	NULL
relatively	NULL
long-lasting	NULL
and	NULL
detectable	NULL
demonstration	NULL
of	NULL
T-ag	NULL
expression	NULL
in	NULL
vivo	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
patient	NULL
13	NULL
)	NULL
,	NULL
these	NULL
results	NULL
also	NULL
indicate	NULL
that	NULL
reactivations	NULL
are	NULL
rather	NULL
rare	NULL
both	NULL
among	NULL
and	NULL
within	NULL
normal	NULL
individuals	NULL
.	NULL

The	NULL
opposite	NULL
result	NULL
is	NULL
observed	NULL
in	NULL
HIV-infected	NULL
individuals	NULL
(	NULL
22	NULL
,	NULL
42	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
among	NULL
such	NULL
patients	NULL
anti-dsDNA	NULL
antibodies	NULL
are	NULL
2052	NULL
-	NULL
Rekvig	NULL
et	NULL
al	NULL
.	NULL

detected	NULL
by	NULL
ELISA	NULL
(	NULL
43	NULL
)	NULL
or	NULL
by	NULL
the	NULL
Crithidia	NULL
test	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Polyomavirus	NULL
reactivations	NULL
may	NULL
therefore	NULL
explain	NULL
development	NULL
of	NULL
anti-DNA	NULL
antibodies	NULL
generally	NULL
,	NULL
and	NULL
not	NULL
exclusively	NULL
for	NULL
SLE	NULL
patients	NULL
.	NULL

This	NULL
is	NULL
also	NULL
demonstrated	NULL
in	NULL
the	NULL
present	NULL
report	NULL
for	NULL
one	NULL
out	NULL
of	NULL
six	NULL
RA	NULL
patients	NULL
.	NULL

Recurrent	NULL
expression	NULL
of	NULL
polyomaviruses	NULL
,	NULL
typical	NULL
for	NULL
SLE	NULL
,	NULL
may	NULL
for	NULL
the	NULL
following	NULL
reasons	NULL
also	NULL
form	NULL
the	NULL
structural	NULL
bases	NULL
for	NULL
the	NULL
progressive	NULL
generation	NULL
of	NULL
antibodies	NULL
to	NULL
dsDNA	NULL
.	NULL

The	NULL
specificity	NULL
for	NULL
dsDNA	NULL
is	NULL
determined	NULL
by	NULL
structural	NULL
properties	NULL
of	NULL
the	NULL
V-region	NULL
of	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
,	NULL
including	NULL
arginines	NULL
in	NULL
the	NULL
complementary	NULL
determining	NULL
region	NULL
(	NULL
CDR	NULL
)	NULL
III	NULL
region	NULL
(	NULL
5	NULL
,	NULL
7	NULL
,	NULL
44	NULL
)	NULL
.	NULL

In	NULL
autoimmune	NULL
mice	NULL
,	NULL
such	NULL
structures	NULL
seem	NULL
to	NULL
result	NULL
from	NULL
progressive	NULL
development	NULL
of	NULL
an	NULL
early	NULL
ssDNA	NULL
antibody	NULL
repertoire	NULL
to	NULL
include	NULL
specificity	NULL
for	NULL
dsDNA	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
antibodies	NULL
to	NULL
ssDNA	NULL
may	NULL
serve	NULL
as	NULL
precursor	NULL
antibodies	NULL
for	NULL
anti-dsDNA	NULL
antibodies	NULL
.	NULL

Compatible	NULL
results	NULL
have	NULL
been	NULL
obtained	NULL
after	NULL
extensive	NULL
immunizations	NULL
with	NULL
CT	NULL
DNA	NULL
complexed	NULL
with	NULL
Fus1	NULL
(	NULL
9	NULL
)	NULL
,	NULL
or	NULL
with	NULL
polyomavirus	NULL
BK	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Intermittent	NULL
or	NULL
persistent	NULL
T-ag	NULL
expression	NULL
in	NULL
man	NULL
may	NULL
be	NULL
a	NULL
natural	NULL
parallel	NULL
to	NULL
such	NULL
experimental	NULL
immunizations	NULL
,	NULL
creating	NULL
the	NULL
molecular	NULL
bases	NULL
for	NULL
a	NULL
continuous	NULL
stimulation	NULL
of	NULL
B	NULL
cells	NULL
specific	NULL
for	NULL
DNA	NULL
.	NULL

Through	NULL
somatic	NULL
mutations	NULL
resulting	NULL
in	NULL
accumulation	NULL
of	NULL
structures	NULL
predisposing	NULL
for	NULL
dsDNA	NULL
binding	NULL
(	NULL
like	NULL
arginines	NULL
in	NULL
the	NULL
CDR	NULL
III	NULL
of	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
)	NULL
,	NULL
such	NULL
antibodies	NULL
may	NULL
also	NULL
obtain	NULL
specificity	NULL
for	NULL
dsDNA	NULL
(	NULL
7	NULL
,	NULL
44	NULL
)	NULL
.	NULL

From	NULL
this	NULL
observation	NULL
,	NULL
one	NULL
may	NULL
predict	NULL
that	NULL
the	NULL
processes	NULL
responsible	NULL
for	NULL
initiation	NULL
of	NULL
antibodies	NULL
to	NULL
dsDNA	NULL
may	NULL
be	NULL
the	NULL
same	NULL
as	NULL
that	NULL
responsible	NULL
for	NULL
initiation	NULL
of	NULL
antibodies	NULL
to	NULL
ssDNA	NULL
.	NULL

Alternatively	NULL
,	NULL
continuous	NULL
stimulation	NULL
by	NULL
DNA	NULL
in	NULL
an	NULL
immunogenic	NULL
form	NULL
may	NULL
also	NULL
recruit	NULL
B	NULL
cells	NULL
with	NULL
an	NULL
inherent	NULL
specificity	NULL
for	NULL
dsDNA	NULL
because	NULL
of	NULL
incomplete	NULL
deletion	NULL
of	NULL
such	NULL
cells	NULL
(	NULL
45	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
seven	NULL
patients	NULL
,	NULL
all	NULL
belonging	NULL
to	NULL
group	NULL
IV	NULL
,	NULL
produced	NULL
anti-dsDNA	NULL
antibodies	NULL
is	NULL
consistent	NULL
with	NULL
these	NULL
interpretations	NULL
.	NULL

Sustained	NULL
or	NULL
recurrent	NULL
expression	NULL
of	NULL
T-ag	NULL
and	NULL
subsequent	NULL
binding	NULL
to	NULL
DNA	NULL
may	NULL
represent	NULL
one	NULL
molecular	NULL
basis	NULL
for	NULL
such	NULL
continuous	NULL
stimulation	NULL
of	NULL
B-cells	NULL
specific	NULL
for	NULL
DNA	NULL
.	NULL

That	NULL
other	NULL
biologically	NULL
active	NULL
processes	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
initiation	NULL
of	NULL
anti-DNA	NULL
antibody	NULL
responses	NULL
have	NULL
not	NULL
been	NULL
excluded	NULL
(	NULL
see	NULL
patient	NULL
19	NULL
of	NULL
the	NULL
present	NULL
study	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
specific	NULL
for	NULL
histones	NULL
,	NULL
for	NULL
example	NULL
,	NULL
may	NULL
both	NULL
initiate	NULL
and	NULL
maintain	NULL
antiDNA	NULL
antibody	NULL
responses	NULL
in	NULL
SLE	NULL
by	NULL
processes	NULL
similar	NULL
to	NULL
those	NULL
described	NULL
for	NULL
T-ag	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
recent	NULL
results	NULL
from	NULL
Desai-Mehta	NULL
et	NULL
al	NULL
.	NULL

(	NULL
46	NULL
)	NULL
.	NULL

These	NULL
two	NULL
systems	NULL
are	NULL
quite	NULL
similar	NULL
,	NULL
however	NULL
,	NULL
with	NULL
the	NULL
principal	NULL
difference	NULL
being	NULL
that	NULL
in	NULL
the	NULL
polyomavirus	NULL
model	NULL
,	NULL
T	NULL
cells	NULL
recognize	NULL
a	NULL
nonself	NULL
protein	NULL
(	NULL
T-ag	NULL
)	NULL
,	NULL
while	NULL
in	NULL
the	NULL
system	NULL
described	NULL
by	NULL
Desai-Mehta	NULL
et	NULL
al	NULL
.	NULL

,	NULL
T	NULL
cells	NULL
recognize	NULL
self	NULL
proteins	NULL
contained	NULL
within	NULL
the	NULL
nucleosomes	NULL
.	NULL

These	NULL
two	NULL
pathways	NULL
are	NULL
,	NULL
however	NULL
,	NULL
not	NULL
mutually	NULL
exclusive	NULL
,	NULL
and	NULL
may	NULL
overlap	NULL
each	NULL
other	NULL
within	NULL
the	NULL
same	NULL
patient	NULL
,	NULL
or	NULL
may	NULL
substitute	NULL
for	NULL
each	NULL
other	NULL
in	NULL
different	NULL
SLE	NULL
patients	NULL
.	NULL

We	NULL
can	NULL
not	NULL
entirely	NULL
rule	NULL
out	NULL
that	NULL
both	NULL
anti-DNA	NULL
antibodies	NULL
and	NULL
polyomavirus	NULL
reactivations	NULL
may	NULL
independently	NULL
arise	NULL
from	NULL
an	NULL
underlying	NULL
yet	NULL
undefined	NULL
proximal	NULL
cause	NULL
.	NULL

The	NULL
consistent	NULL
results	NULL
obtained	NULL
in	NULL
an	NULL
experimental	NULL
context	NULL
in	NULL
mice	NULL
and	NULL
in	NULL
a	NULL
natural	NULL
context	NULL
in	NULL
SLE	NULL
patients	NULL
,	NULL
however	NULL
,	NULL
demonstrating	NULL
a	NULL
statistically	NULL
highly	NULL
significant	NULL
association	NULL
between	NULL
antibodies	NULL
to	NULL
T-ag	NULL
and	NULL
to	NULL
DNA	NULL
,	NULL
support	NULL
the	NULL
view	NULL
that	NULL
spontaneous	NULL
expression	NULL
of	NULL
the	NULL
virus	NULL
alone	NULL
represents	NULL
one	NULL
basic	NULL
process	NULL
for	NULL
induction	NULL
of	NULL
anti-DNA	NULL
autoantibody	NULL
production	NULL
.	NULL

The	NULL
results	NULL
described	NULL
in	NULL
this	NULL
report	NULL
are	NULL
particularly	NULL
attractive	NULL
in	NULL
light	NULL
of	NULL
the	NULL
attempt	NULL
to	NULL
understand	NULL
a	NULL
biological	NULL
origin	NULL
of	NULL
antibodies	NULL
to	NULL
DNA	NULL
within	NULL
a	NULL
natural	NULL
physiological	NULL
context	NULL
.	NULL

For	NULL
a	NULL
latent	NULL
polyomavirus	NULL
to	NULL
reactivate	NULL
,	NULL
this	NULL
process	NULL
is	NULL
initiated	NULL
by	NULL
active	NULL
expression	NULL
of	NULL
the	NULL
T-ag	NULL
.	NULL

One	NULL
consequence	NULL
of	NULL
this	NULL
expression	NULL
is	NULL
binding	NULL
to	NULL
DNA	NULL
,	NULL
necessary	NULL
for	NULL
initiating	NULL
transcriptional	NULL
activity	NULL
of	NULL
virus	NULL
genes	NULL
.	NULL

A	NULL
side	NULL
effect	NULL
is	NULL
also	NULL
binding	NULL
to	NULL
host	NULL
DNA	NULL
,	NULL
thus	NULL
forming	NULL
a	NULL
complex	NULL
between	NULL
host	NULL
cell	NULL
DNA	NULL
and	NULL
T-ag	NULL
.	NULL

This	NULL
process	NULL
allows	NULL
for	NULL
cognate	NULL
interaction	NULL
of	NULL
B	NULL
cells	NULL
specific	NULL
for	NULL
either	NULL
of	NULL
the	NULL
components	NULL
of	NULL
nucleosomes	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
DNA	NULL
and	NULL
histones	NULL
)	NULL
,	NULL
or	NULL
for	NULL
molecules	NULL
physically	NULL
linked	NULL
to	NULL
this	NULL
complex	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
transcription	NULL
factors	NULL
like	NULL
TBP	NULL
or	NULL
CREB	NULL
)	NULL
,	NULL
and	NULL
T-cells	NULL
specific	NULL
for	NULL
T-ag	NULL
,	NULL
processed	NULL
and	NULL
presented	NULL
by	NULL
such	NULL
B-cells	NULL
.	NULL

T-ag	NULL
may	NULL
therefore	NULL
serve	NULL
as	NULL
a	NULL
latent	NULL
biological	NULL
basis	NULL
for	NULL
antiDNA	NULL
antibody	NULL
production	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
here	NULL
and	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
are	NULL
consistent	NULL
with	NULL
this	NULL
interpretation	NULL
,	NULL
and	NULL
are	NULL
compatible	NULL
with	NULL
the	NULL
model	NULL
suggested	NULL
in	NULL
a	NULL
recent	NULL
review	NULL
(	NULL
13	NULL
)	NULL
and	NULL
by	NULL
Radic	NULL
and	NULL
Weigert	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Tony	NULL
N.	NULL
Marion	NULL
for	NULL
his	NULL
helpful	NULL
suggestions	NULL
and	NULL
critical	NULL
comments	NULL
on	NULL
this	NULL
manuscript	NULL
.	NULL

The	NULL
GST	NULL
fusion	NULL
partner	NULL
protein	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Allan	NULL
W.	NULL
Hey	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Grethe	NULL
Harbitz	NULL
Fund	NULL
,	NULL
and	NULL
from	NULL
the	NULL
Tromsg	NULL
University	NULL
Hospital	NULL
Research	NULL
Fund	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Buskila	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Y.	NULL
Shoenfeld	NULL
.	NULL

1992	NULL
.	NULL

Anti-DNA	NULL
antibodies	NULL
.	NULL

In	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
.	NULL

R.G	NULL
.	NULL

Lahita	NULL
,	NULL
editor	NULL
.	NULL

Churchill	NULL
Livingstone	NULL
,	NULL
New	NULL
York/	NULL
Edinburgh/London/Melbourne/Tokyo	NULL
.	NULL

205-236	NULL
.	NULL

2	NULL
.	NULL

Veinstein	NULL
,	NULL
A.	NULL
,	NULL
B.	NULL
Bordwell	NULL
,	NULL
B	NULL
.	NULL

Stone	NULL
,	NULL
C.	NULL
Tibbetts	NULL
,	NULL
and	NULL
N.F	NULL
.	NULL

Rothfield	NULL
.	NULL

1983	NULL
.	NULL

Antibodies	NULL
to	NULL
native	NULL
DNA	NULL
and	NULL
serum	NULL
complement	NULL
(	NULL
C3	NULL
)	NULL
levels	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

74:206-216	NULL
.	NULL

3	NULL
.	NULL

Isenberg	NULL
,	NULL
D.A	NULL
.	NULL

1994	NULL
.	NULL

Anti-DNA	NULL
antibodies-some	NULL
enigma	NULL
variations	NULL
.	NULL

The	NULL
Immunologist	NULL
.	NULL

2:190-193	NULL
.	NULL

4	NULL
.	NULL

Vlahakos	NULL
,	NULL
D.V	NULL
.	NULL

,	NULL
M.H	NULL
.	NULL

Foster	NULL
,	NULL
S.	NULL
Adams	NULL
,	NULL
M.	NULL
Katz	NULL
,	NULL
A.A.	NULL
Ucei	NULL
,	NULL
K.J	NULL
.	NULL

Bar-rett	NULL
,	NULL
S.K	NULL
.	NULL

Datta	NULL
,	NULL
and	NULL
M.P	NULL
.	NULL

Madaio	NULL
.	NULL

1992	NULL
.	NULL

Anti-DNA	NULL
antibodies	NULL
form	NULL
immune	NULL
deposits	NULL
at	NULL
distinct	NULL
glomerular	NULL
and	NULL
vascular	NULL
sites	NULL
.	NULL

Kidney	NULL
Int	NULL
.	NULL

41:1690-1700	NULL
.	NULL

5	NULL
.	NULL

Radic	NULL
,	NULL
M.Z	NULL
.	NULL

,	NULL
and	NULL
M.	NULL
Weigert	NULL
.	NULL

1994	NULL
.	NULL

Genetic	NULL
and	NULL
structural	NULL
evidence	NULL
for	NULL
antigen	NULL
selection	NULL
of	NULL
anti-DNA	NULL
antibodies	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12:487-520	NULL
.	NULL

6	NULL
.	NULL

Marion	NULL
,	NULL
T.N	NULL
.	NULL

,	NULL
D.M	NULL
.	NULL

Tillman	NULL
,	NULL
N.-T.	NULL
Jou	NULL
,	NULL
and	NULL
R.J.	NULL
Hill	NULL
.	NULL

1992	NULL
.	NULL

Selection	NULL
of	NULL
immunoglobulin	NULL
variable	NULL
regions	NULL
in	NULL
autoimmunity	NULL
to	NULL
DNA	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

128	NULL
:	NULL
123-149	NULL
.	NULL

7	NULL
.	NULL

Radic	NULL
,	NULL
M.Z	NULL
.	NULL

,	NULL
J.	NULL
Mackle	NULL
,	NULL
J.	NULL
Erikson	NULL
,	NULL
C.	NULL
Mol	NULL
,	NULL
W.F	NULL
.	NULL

Anderson	NULL
,	NULL
and	NULL
M.	NULL
Weigert	NULL
.	NULL

1993	NULL
.	NULL

Residues	NULL
that	NULL
mediate	NULL
DNA	NULL
binding	NULL
of	NULL
autoimmune	NULL
antibodies	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

150:4966-4977	NULL
.	NULL

8	NULL
.	NULL

Marion	NULL
,	NULL
TN	NULL
.	NULL

,	NULL
D.M	NULL
.	NULL

Tillman	NULL
,	NULL
and	NULL
N.-T.	NULL
Jou	NULL
.	NULL

1990	NULL
.	NULL

Interclonal	NULL
and	NULL
intra-clonal	NULL
diversity	NULL
among	NULL
anti-DNA	NULL
antibodies	NULL
from	NULL
an	NULL
(	NULL
NZB	NULL
x	NULL
NZW	NULL
)	NULL
F	NULL
,	NULL
mouse	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:2322-2332	NULL
.	NULL

9	NULL
.	NULL

Desai	NULL
,	NULL
D.D	NULL
.	NULL

,	NULL
M.R	NULL
.	NULL

Krishnan	NULL
,	NULL
J.T	NULL
.	NULL

Swindle	NULL
,	NULL
and	NULL
T.N	NULL
.	NULL

Marion	NULL
.	NULL

1993	NULL
.	NULL

Anti-gen-specific	NULL
induction	NULL
of	NULL
antibodies	NULL
against	NULL
native	NULL
mammalian	NULL
DNA	NULL
in	NULL
nonau-toimmune	NULL
mice	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:1614-1626	NULL
.	NULL

10	NULL
.	NULL

Krishnan	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
and	NULL
TN	NULL
.	NULL

Marion	NULL
.	NULL

1993	NULL
.	NULL

Structural	NULL
similarity	NULL
of	NULL
antibody	NULL
variable	NULL
regions	NULL
from	NULL
immune	NULL
and	NULL
autoimmune	NULL
anti-DNA	NULL
antibodies	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

150:4948-4957	NULL
.	NULL

11	NULL
.	NULL

Rekvig	NULL
,	NULL
O.P	NULL
.	NULL

,	NULL
K.	NULL
Fredriksen	NULL
,	NULL
K.	NULL
Hokland	NULL
,	NULL
U.	NULL
Moens	NULL
,	NULL
T.	NULL
Traavik	NULL
,	NULL
MR.	NULL
Krishnan	NULL
,	NULL
and	NULL
TN	NULL
.	NULL

Marion	NULL
.	NULL

1995	NULL
.	NULL

Molecular	NULL
analyses	NULL
of	NULL
anti-DNA	NULL
antibodies	NULL
induced	NULL
by	NULL
Polyomavirus	NULL
BK	NULL
in	NULL
Balb/C	NULL
mice	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

41:593-602	NULL
.	NULL

12	NULL
.	NULL

Flaegstad	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Fredriksen	NULL
,	NULL
B.	NULL
Dahl	NULL
,	NULL
T.	NULL
Traavik	NULL
,	NULL
and	NULL
O.P	NULL
.	NULL

Rekvig	NULL
.	NULL

1988	NULL
.	NULL

Inoculation	NULL
with	NULL
BK	NULL
virus	NULL
may	NULL
lead	NULL
to	NULL
break	NULL
of	NULL
immunological	NULL
tolerance	NULL
to	NULL
histone	NULL
and	NULL
DNA	NULL
antigens	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

85:8171-8175	NULL
.	NULL

13	NULL
.	NULL

Rekvig	NULL
,	NULL
O.P	NULL
.	NULL

,	NULL
J.	NULL
Moens	NULL
,	NULL
K.	NULL
Fredriksen	NULL
,	NULL
and	NULL
T.	NULL
Traavik	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
polyomavirus	NULL
BK	NULL
and	NULL
immunogenicity	NULL
of	NULL
mammalian	NULL
DNA	NULL
:	NULL
A	NULL
conceptual	NULL
framework	NULL
.	NULL

Methods	NULL
.	NULL

11:44-54	NULL
.	NULL

14	NULL
.	NULL

Moens	NULL
,	NULL
U.	NULL
,	NULL
O.-M.	NULL
Seternes	NULL
,	NULL
A.W	NULL
.	NULL

Hey	NULL
,	NULL
Y.	NULL
Silsand	NULL
,	NULL
T.	NULL
Traavik	NULL
,	NULL
B.	NULL
Johansen	NULL
,	NULL
and	NULL
O.P	NULL
.	NULL

Rekvig	NULL
.	NULL

1995	NULL
.	NULL

In	NULL
vivo	NULL
expression	NULL
of	NULL
a	NULL
single	NULL
viral	NULL
DNA-binding	NULL
protein	NULL
generates	NULL
systemic	NULL
lupus	NULL
erythematosus-related	NULL
autoimmunity	NULL
to	NULL
double-stranded	NULL
DNA	NULL
and	NULL
histones	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

92:12393-12397	NULL
.	NULL

15	NULL
.	NULL

Yoshiike	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
K.K	NULL
.	NULL

Takemoto	NULL
.	NULL

1986	NULL
.	NULL

Studies	NULL
with	NULL
BK	NULL
virus	NULL
and	NULL
monkey	NULL
lymphotropic	NULL
papovavirus	NULL
.	NULL

In	NULL
The	NULL
Papoviridae	NULL
,	NULL
Volume	NULL
1	NULL
.	NULL

N.P	NULL
.	NULL

Salzman	NULL
,	NULL
editor	NULL
.	NULL

Plenum	NULL
Publishing	NULL
Corp.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

295-326	NULL
.	NULL

16	NULL
.	NULL

Brown	NULL
,	NULL
P.T	NULL
.	NULL

,	NULL
T.	NULL
Tsai	NULL
,	NULL
and	NULL
D.C.	NULL
Gajdusek	NULL
.	NULL

1975	NULL
.	NULL

Seroepidemiology	NULL
of	NULL
human	NULL
papovaviruses	NULL
.	NULL

Discovery	NULL
of	NULL
virgin	NULL
populations	NULL
and	NULL
some	NULL
unusual	NULL
patterns	NULL
of	NULL
antibody	NULL
prevalence	NULL
among	NULL
remote	NULL
people	NULL
of	NULL
the	NULL
world	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Epidemiol	NULL
.	NULL

102:331-340	NULL
.	NULL

17	NULL
.	NULL

Heritage	NULL
,	NULL
J.	NULL
,	NULL
P.M.	NULL
Chesters	NULL
,	NULL
and	NULL
D.J	NULL
.	NULL

McCance	NULL
.	NULL

1981	NULL
.	NULL

The	NULL
persistence	NULL
of	NULL
papovavirus	NULL
BK	NULL
DNA	NULL
sequences	NULL
in	NULL
normal	NULL
human	NULL
renal	NULL
tissue	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Virol	NULL
.	NULL

8	NULL
:	NULL
143-150	NULL
.	NULL

18	NULL
.	NULL

Latchman	NULL
,	NULL
D.S	NULL
.	NULL

Eukaryotic	NULL
Transcription	NULL
Factors	NULL
.	NULL

2nd	NULL
ed	NULL
.	NULL

1995	NULL
.	NULL

Academic	NULL
Press/Harcourt	NULL
Brace	NULL
and	NULL
Co.	NULL
,	NULL
London	NULL
.	NULL

55-59	NULL
.	NULL

19	NULL
.	NULL

Lee	NULL
,	NULL
K.A.W	NULL
.	NULL

,	NULL
and	NULL
N.	NULL
Masson	NULL
.	NULL

1993	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
by	NULL
CREB	NULL
and	NULL
its	NULL
relatives	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
.	NULL

1174:221-233	NULL
.	NULL

20	NULL
.	NULL

Tan	NULL
,	NULL
E.M.	NULL
,	NULL
A.S.	NULL
Cohen	NULL
,	NULL
J.F	NULL
.	NULL

Fries	NULL
,	NULL
A.T.	NULL
Masi	NULL
,	NULL
D.J	NULL
.	NULL

McShane	NULL
,	NULL
N.F	NULL
.	NULL

Roth-field	NULL
,	NULL
J.G	NULL
.	NULL

Schaller	NULL
,	NULL
N.	NULL
Talal	NULL
,	NULL
and	NULL
R.J.	NULL
Winchester	NULL
.	NULL

1982	NULL
.	NULL

The	NULL
1982	NULL
revised	NULL
criteria	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

25	NULL
:	NULL
1271-1277	NULL
.	NULL

21	NULL
.	NULL

Kwok	NULL
,	NULL
S.	NULL
1992	NULL
.	NULL

Procedures	NULL
to	NULL
minimize	NULL
PCR-product	NULL
carry-over	NULL
.	NULL

In	NULL
PCR	NULL
Protocols	NULL
.	NULL

A	NULL
Guide	NULL
to	NULL
Methods	NULL
and	NULL
Applications	NULL
.	NULL

M.A	NULL
.	NULL

Innis	NULL
,	NULL
D.H.	NULL
Gel-fand	NULL
,	NULL
J.J.	NULL
Sninsky	NULL
,	NULL
and	NULL
T.J.	NULL
White	NULL
,	NULL
editors	NULL
.	NULL

Academic	NULL
Press	NULL
,	NULL
Inc.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
.	NULL

142-145	NULL
.	NULL

22	NULL
.	NULL

Sundsfjord	NULL
,	NULL
A.	NULL
,	NULL
T.	NULL
Flegstad	NULL
,	NULL
R.	NULL
Flg	NULL
,	NULL
A.R	NULL
.	NULL

Spein	NULL
,	NULL
M.	NULL
Pedersen	NULL
,	NULL
H.	NULL
Per-min	NULL
,	NULL
J.	NULL
Julsrud	NULL
,	NULL
and	NULL
T.	NULL
Traavik	NULL
.	NULL

1994	NULL
.	NULL

BK	NULL
and	NULL
JC	NULL
viruses	NULL
in	NULL
human	NULL
immunodefi-ciency	NULL
virus	NULL
type	NULL
1-infected	NULL
persons	NULL
:	NULL
prevalence	NULL
,	NULL
excretion	NULL
,	NULL
viremia	NULL
,	NULL
and	NULL
viral	NULL
regulatory	NULL
regions	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

169:485-490	NULL
.	NULL

23	NULL
.	NULL

Bergsagel	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
M.J.	NULL
Finegold	NULL
,	NULL
J.	NULL
Butel	NULL
,	NULL
W.J	NULL
.	NULL

Kupsky	NULL
,	NULL
and	NULL
R.L	NULL
.	NULL

Garcea	NULL
.	NULL

1992	NULL
.	NULL

DNA	NULL
sequences	NULL
similiar	NULL
to	NULL
those	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
in	NULL
ependymomas	NULL
and	NULL
choroid	NULL
plexus	NULL
tumors	NULL
of	NULL
childhood	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

326:988-993	NULL
.	NULL

24	NULL
.	NULL

Flegstad	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Sundsfjord	NULL
,	NULL
RR	NULL
.	NULL

Arthur	NULL
,	NULL
M.	NULL
Pedersen	NULL
,	NULL
T.	NULL
Traavik	NULL
,	NULL
and	NULL
S.	NULL
Subramani	NULL
.	NULL

1991	NULL
.	NULL

Amplification	NULL
and	NULL
sequencing	NULL
of	NULL
the	NULL
control	NULL
regions	NULL
of	NULL
BK	NULL
and	NULL
JC	NULL
virus	NULL
from	NULL
human	NULL
urine	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Virology	NULL
.	NULL

180	NULL
:	NULL
553-560	NULL
.	NULL

25	NULL
.	NULL

Sundsfjord	NULL
,	NULL
A.	NULL
,	NULL
T.	NULL
Johansen	NULL
,	NULL
T.	NULL
Flegstad	NULL
,	NULL
U.	NULL
Moens	NULL
,	NULL
P.	NULL
Villand	NULL
,	NULL
S.	NULL
Sub-ramani	NULL
,	NULL
and	NULL
T.	NULL
Traavik	NULL
.	NULL

1990	NULL
.	NULL

At	NULL
least	NULL
two	NULL
types	NULL
of	NULL
control	NULL
regions	NULL
can	NULL
be	NULL
found	NULL
among	NULL
naturally	NULL
occurring	NULL
BK	NULL
virus	NULL
strains	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3864-3871	NULL
.	NULL

26	NULL
.	NULL

Sundsfjord	NULL
,	NULL
A.	NULL
,	NULL
A.R	NULL
.	NULL

Spein	NULL
,	NULL
E.	NULL
Lucht	NULL
,	NULL
T.	NULL
Fleegstad	NULL
,	NULL
O.M	NULL
.	NULL

Seternes	NULL
,	NULL
and	NULL
T.	NULL
Traavik	NULL
.	NULL

1994	NULL
.	NULL

Detection	NULL
of	NULL
BK	NULL
virus	NULL
DNA	NULL
in	NULL
nasopharyngeal	NULL
aspirates	NULL
from	NULL
children	NULL
with	NULL
respiratory	NULL
infections	NULL
but	NULL
not	NULL
in	NULL
saliva	NULL
from	NULL
immunodeficient	NULL
and	NULL
immunocompetent	NULL
adult	NULL
patients	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

32:1390-1394	NULL
.	NULL

27	NULL
.	NULL

Sanger	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
Nicklen	NULL
,	NULL
and	NULL
A.R	NULL
.	NULL

Coulson	NULL
.	NULL

1977	NULL
.	NULL

DNA	NULL
sequencing	NULL
with	NULL
chain-terminating	NULL
inhibitors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

74:5463-5467	NULL
.	NULL

28	NULL
.	NULL

Fredriksen	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Traavik	NULL
,	NULL
and	NULL
O.P	NULL
.	NULL

Rekvig	NULL
.	NULL

1990	NULL
.	NULL

Anti-DNA	NULL
antibodies	NULL
induced	NULL
by	NULL
BK	NULL
virus	NULL
inoculations	NULL
.	NULL

Demonstration	NULL
of	NULL
the	NULL
specificities	NULL
for	NULL
eukaryotic	NULL
dsDNA	NULL
and	NULL
synthetic	NULL
poly-nucleotides	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

32:197-203	NULL
.	NULL

29	NULL
.	NULL

Tillman	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
N.T	NULL
.	NULL

Jou	NULL
,	NULL
R.J.	NULL
Hill	NULL
,	NULL
and	NULL
T.N	NULL
.	NULL

Marion	NULL
.	NULL

1992	NULL
.	NULL

Both	NULL
IgM	NULL
and	NULL
IgG	NULL
anti-DNA	NULL
antibodies	NULL
are	NULL
the	NULL
products	NULL
of	NULL
clonally	NULL
selective	NULL
B-cell	NULL
stimulation	NULL
in	NULL
(	NULL
NZB	NULL
X	NULL
NZW	NULL
)	NULL
F	NULL
,	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:761-779	NULL
.	NULL

30	NULL
.	NULL

Simmons	NULL
,	NULL
D.T	NULL
.	NULL

,	NULL
K.	NULL
Wun-Kim	NULL
,	NULL
and	NULL
W.	NULL
Young	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
T-antigen	NULL
residues	NULL
important	NULL
for	NULL
specific	NULL
and	NULL
non-specific	NULL
binding	NULL
to	NULL
DNA	NULL
and	NULL
to	NULL
helicase	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:4858-4865	NULL
.	NULL

31	NULL
.	NULL

Moens	NULL
,	NULL
U.	NULL
,	NULL
T.	NULL
Johansen	NULL
,	NULL
J.I	NULL
.	NULL

Johnsen	NULL
,	NULL
O.M	NULL
.	NULL

Seternes	NULL
,	NULL
and	NULL
T.	NULL
Traavik	NULL
.	NULL

1995	NULL
.	NULL

Noncoding	NULL
control	NULL
region	NULL
of	NULL
naturally	NULL
occuring	NULL
BK	NULL
virus	NULL
variants	NULL
:	NULL
sequence	NULL
comparison	NULL
and	NULL
functional	NULL
analysis	NULL
.	NULL

Virus	NULL
Genes	NULL
.	NULL

10:261-275	NULL
.	NULL

32	NULL
.	NULL

Moens	NULL
,	NULL
U.	NULL
,	NULL
N.	NULL
Subramaniam	NULL
,	NULL
B.	NULL
Johansen	NULL
,	NULL
T.	NULL
Johansen	NULL
,	NULL
and	NULL
T.	NULL
Traavik	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
steroid	NULL
hormone	NULL
response	NULL
unit	NULL
in	NULL
the	NULL
late	NULL
leader	NULL
of	NULL
the	NULL
noncoding	NULL
control	NULL
region	NULL
of	NULL
the	NULL
human	NULL
polyomavirus	NULL
BK	NULL
confers	NULL
enhanced	NULL
host	NULL
cell	NULL
permis-sivity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2398-2408	NULL
.	NULL

33	NULL
.	NULL

Fredriksen	NULL
,	NULL
K	NULL
,	NULL
A.	NULL
Osei	NULL
,	NULL
A.	NULL
Sundsfjord	NULL
,	NULL
T.	NULL
Traavik	NULL
,	NULL
and	NULL
O.P	NULL
.	NULL

Rekvig	NULL
.	NULL

1994	NULL
.	NULL

On	NULL
the	NULL
biological	NULL
origin	NULL
of	NULL
anti-double-stranded	NULL
(	NULL
ds	NULL
)	NULL
DNA	NULL
antibodies	NULL
:	NULL
systemic	NULL
lupus	NULL
erythematosus-related	NULL
anti-dsDNA	NULL
antibodies	NULL
are	NULL
induced	NULL
by	NULL
polyomavirus	NULL
BK	NULL
in	NULL
lupus-prone	NULL
(	NULL
NZB	NULL
X	NULL
NZW	NULL
)	NULL
F	NULL
;	NULL
hybrids	NULL
,	NULL
but	NULL
not	NULL
in	NULL
normal	NULL
mice	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:66-70	NULL
.	NULL

34	NULL
.	NULL

Johnston	NULL
,	NULL
S.D	NULL
.	NULL

,	NULL
X.-M.	NULL
Yu	NULL
,	NULL
and	NULL
J.E	NULL
.	NULL

Mertz	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
major	NULL
transcriptional	NULL
transactivation	NULL
domain	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
large	NULL
T	NULL
antigen	NULL
associates	NULL
non-concurrently	NULL
with	NULL
multiple	NULL
components	NULL
of	NULL
the	NULL
transcriptional	NULL
preinitiation	NULL
complex	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:1191-1202	NULL
.	NULL

35	NULL
.	NULL

Gruss	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Wetzel	NULL
,	NULL
M.	NULL
Baack	NULL
,	NULL
U.	NULL
Mock	NULL
,	NULL
and	NULL
R.	NULL
Knippers	NULL
.	NULL

1988	NULL
.	NULL

High	NULL
affinity	NULL
SV40	NULL
T-antigen	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
human	NULL
genome	NULL
.	NULL

Virology	NULL
.	NULL

167:349-360	NULL
.	NULL

36	NULL
.	NULL

Marrero	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Garbarg-Chenon	NULL
,	NULL
G.	NULL
de	NULL
Saint-Maur	NULL
,	NULL
P.	NULL
Fanen	NULL
,	NULL
E.	NULL
Rousseau	NULL
,	NULL
M.	NULL
Alvarez	NULL
,	NULL
J.C.	NULL
Nicolas	NULL
,	NULL
and	NULL
F.	NULL
Bricout	NULL
.	NULL

1989	NULL
.	NULL

BK	NULL
virus	NULL
(	NULL
BKV	NULL
)	NULL
detection	NULL
in	NULL
urine	NULL
specimens	NULL
of	NULL
immunocompromized	NULL
patients	NULL
:	NULL
Comparison	NULL
between	NULL
the	NULL
DNA-DNA	NULL
hybridization	NULL
assay	NULL
,	NULL
the	NULL
immunofluorescence	NULL
test	NULL
and	NULL
the	NULL
dot	NULL
enzyme	NULL
immunoassay	NULL
.	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

140:293-301	NULL
.	NULL

37	NULL
.	NULL

Arthur	NULL
,	NULL
R.R	NULL
.	NULL

,	NULL
S.	NULL
Dagostin	NULL
,	NULL
and	NULL
K.V	NULL
.	NULL

Shah	NULL
.	NULL

1989	NULL
.	NULL

Detection	NULL
of	NULL
BK	NULL
virus	NULL
and	NULL
JC	NULL
virus	NULL
in	NULL
urine	NULL
and	NULL
brain	NULL
tissue	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

27:1174-1179	NULL
.	NULL

38	NULL
.	NULL

Arthur	NULL
,	NULL
RR	NULL
.	NULL

,	NULL
K.V	NULL
.	NULL

Shah	NULL
,	NULL
P.	NULL
Charache	NULL
,	NULL
and	NULL
R.	NULL
Saral	NULL
.	NULL

1988	NULL
.	NULL

BK	NULL
and	NULL
JC	NULL
virus	NULL
infections	NULL
in	NULL
recipients	NULL
of	NULL
bone	NULL
marrow	NULL
transplants	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

158:563-569	NULL
.	NULL

39	NULL
.	NULL

Hogan	NULL
,	NULL
TF	NULL
.	NULL

,	NULL
B.L	NULL
.	NULL

Padgett	NULL
,	NULL
D.L	NULL
.	NULL

Walker	NULL
,	NULL
E.C	NULL
.	NULL

Borden	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
McBain	NULL
.	NULL

1980	NULL
.	NULL

Rapid	NULL
detection	NULL
and	NULL
identification	NULL
of	NULL
JC	NULL
virus	NULL
and	NULL
BK	NULL
virus	NULL
in	NULL
human	NULL
urine	NULL
by	NULL
using	NULL
immunofluorescence	NULL
microscopy	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

11:178-183	NULL
.	NULL

40	NULL
.	NULL

Marshall	NULL
,	NULL
W.F	NULL
.	NULL

,	NULL
A.	NULL
Telenti	NULL
,	NULL
J	NULL
.	NULL

Proper	NULL
,	NULL
A.J	NULL
.	NULL

Aksamit	NULL
,	NULL
and	NULL
T.F	NULL
.	NULL

Smith	NULL
.	NULL

1991	NULL
.	NULL

Survey	NULL
of	NULL
urine	NULL
from	NULL
transplant	NULL
recipients	NULL
for	NULL
polyomaviruses	NULL
JC	NULL
and	NULL
BK	NULL
using	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Probes	NULL
.	NULL

5:125-128	NULL
.	NULL

41	NULL
.	NULL

Takemoto	NULL
,	NULL
K.K	NULL
.	NULL

1980	NULL
.	NULL

Human	NULL
polyomaviruses	NULL
:	NULL
Evaluation	NULL
of	NULL
their	NULL
pos-	NULL
Polyomaviruses	NULL
and	NULL
Autoimmunity	NULL
to	NULL
DNA	NULL
in	NULL
SLE	NULL
__	NULL
2053	NULL
sible	NULL
involvement	NULL
in	NULL
human	NULL
cancer	NULL
.	NULL

/n	NULL
Viruses	NULL
in	NULL
Naturally	NULL
Occuring	NULL
Cancers	NULL
.	NULL

M.	NULL
Essex	NULL
,	NULL
G.	NULL
Todaro	NULL
,	NULL
and	NULL
M.	NULL
zur	NULL
Hausen	NULL
,	NULL
editors	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Conference	NULL
on	NULL
Cell	NULL
Proliferation	NULL
.	NULL

Volume	NULL
7	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
New	NULL
York	NULL
.	NULL

311-318	NULL
.	NULL

42	NULL
.	NULL

Markowitz	NULL
,	NULL
R.B	NULL
.	NULL

,	NULL
H.C.	NULL
Thompson	NULL
,	NULL
J.F	NULL
.	NULL

Mueller	NULL
,	NULL
J.A	NULL
.	NULL

Cohen	NULL
,	NULL
and	NULL
W.S	NULL
.	NULL

Dynan	NULL
.	NULL

1993	NULL
.	NULL

Incidence	NULL
of	NULL
BK	NULL
virus	NULL
and	NULL
JC	NULL
virus	NULL
viruria	NULL
in	NULL
human	NULL
immunodefi-ciency	NULL
virus-infected	NULL
and	NULL
-uninfected	NULL
subjects	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

167:13-20	NULL
.	NULL

43	NULL
.	NULL

Muller	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Richalet	NULL
,	NULL
A.	NULL
Laurent-Crawford	NULL
,	NULL
S.	NULL
Barakat	NULL
,	NULL
Y.	NULL
Riviere	NULL
,	NULL
F.	NULL
Porrot	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
J.-P.	NULL
Briand	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
and	NULL
A.	NULL
Hovanessian	NULL
.	NULL

1992	NULL
.	NULL

Autoantibodies	NULL
typical	NULL
of	NULL
non-organ-specific	NULL
autoimmune	NULL
diseases	NULL
in	NULL
HIV-seropositive	NULL
patients	NULL
.	NULL

AIDS	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

6:933-942	NULL
.	NULL

2054	NULL
_-	NULL
Rekvig	NULL
et	NULL
al	NULL
.	NULL

44	NULL
.	NULL

Krishnan	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
N.T	NULL
.	NULL

Jou	NULL
,	NULL
and	NULL
T.N	NULL
.	NULL

Marion	NULL
.	NULL

1996	NULL
.	NULL

Correlation	NULL
between	NULL
the	NULL
amino	NULL
acid	NULL
position	NULL
of	NULL
arginine	NULL
in	NULL
VH-CDR3	NULL
and	NULL
specificity	NULL
for	NULL
native	NULL
DNA	NULL
among	NULL
autoimmune	NULL
antibodies	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:2430-2439	NULL
.	NULL

45	NULL
.	NULL

Chen	NULL
,	NULL
C.	NULL
,	NULL
Z.	NULL
Nagy	NULL
,	NULL
M.Z	NULL
.	NULL

Radic	NULL
,	NULL
RR	NULL
.	NULL

Hardy	NULL
,	NULL
D.	NULL
Huszar	NULL
,	NULL
S.A	NULL
.	NULL

Camper	NULL
,	NULL
and	NULL
M.	NULL
Weigert	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
site	NULL
and	NULL
stage	NULL
of	NULL
anti-DNA	NULL
B-cell	NULL
deletion	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

373:252-255	NULL
.	NULL

46	NULL
.	NULL

Desai-Mehta	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
Mao	NULL
,	NULL
S.	NULL
Rajagopalan	NULL
,	NULL
T.	NULL
Robinson	NULL
,	NULL
and	NULL
S.K	NULL
.	NULL

Datta	NULL
.	NULL

1995	NULL
.	NULL

Structure	NULL
and	NULL
specificity	NULL
of	NULL
T	NULL
cell	NULL
receptors	NULL
expressed	NULL
by	NULL
potentially	NULL
pathogenic	NULL
anti-DNA	NULL
autoantibody-inducing	NULL
T	NULL
cells	NULL
in	NULL
human	NULL
lupus	NULL
.	NULL

J.	NULL
Cin	NULL
.	NULL

Invest	NULL
.	NULL

95:531-541	NULL
.	NULL

